Impairment of insulin signaling cascade favors the development of Alzheimer disease pathology by altering APP processing in the brain by Triani, Francesca
PHD IN BIOCHEMISTRY 
CYCLE XXXI (A.A. 2015-2018) 
Impairment of insulin signaling cascade favors 
the development of Alzheimer disease pathology 
by altering APP processing in the brain 
Supervisor                   Coordinator 
Dr. Eugenio Barone  Prof.  Stefano Gianni 
PhD Candidate 
 Francesca Triani 
    
 
PHD IN BIOCHEMISTRY 
CYCLE XXXI (A.A. 2015-2018) 
 
 
 
 
Impairment of insulin signaling cascade 
favors the development of Alzheimer 
disease pathology by altering APP 
processing in the brain 
 
 
 
 
Supervisor                                                                    Coordinator  
Dr. Eugenio Barone                                     Prof.  Stefano Gianni 
 
PhD Candidate 
        Francesca Triani 
E senti allora, se pure ti ripetono che puoi, 
fermati a mezza via o in alto mare, 
che non c’è sosta per noi, 
ma strada, ancora strada, 
e che il cammino è sempre da ricominciare. 
Eugenio Montale 
	   2	  
INDEX 
 
1. INTRODUCTION  ......................................................................... 10 	  
1. Alzheimer's  disease  ...................................................................... 10 
1.1 Amyloid precursor protein ........................................................ 13 
         1.1.1 BACE 1 .......................................................................... 16 
           1.1.2 Amyloid beta function .................................................... 19 
   1.2 Oxidative damage ...................................................................... 20 
2. Insulin: structure and biosynthesis  ................................................ 23 
 2.1 Cerebral insulin ......................................................................... 25 
      2.1.1 Mechanisms of insulin signaling transduction in the 
brain ................................................................................................. 26 
       2.1.1.1 PI3K/AKT axis .............................................................. 31 
         2.1.1.2 ERK1/2 cascade ............................................................. 34 
 2.2 Impairment of brain insulin signaling in AD ............................ 34 
      2.2.1 Biliverdin reductase-A ......................................................... 38 
   2.3 Insulin as a therapy for AD ......................................................  42 	  	  
2. AIMS OF THE WORK .................................................................. 44 	  	  
3. MATERIALS AND METHODS ................................................... 46 	  
	   3	  
3.1 Samples ......................................................................................... 46 
   3.1.1 Animals ................................................................................... 46 
   3.1.2 Human AD case ...................................................................... 47 
   3.1.3 Mouse colonies ....................................................................... 47 
3.2 INI treatment  ............................................................................... 48 
3.3 Behavioral test  ............................................................................. 49 
 3.3.1 Novel Object recognition test (NOR) ..................................... 49 
   3.3.2 Morris water maze (MWM) ................................................... 50 
   3.3.3 Forced swim test (FST) .......................................................... 51 
   3.3.4 Tail suspension test (TST) ...................................................... 52 
3.4 Sample preparation for Western Blot ........................................... 52 
3.5 Slot Blot  ....................................................................................... 53 
3.6 Western Blot ................................................................................. 54 
3.7 Immunoprecipitation .................................................................... 57  
3.8 Cell culture and treatments  .......................................................... 58 
3.9 Peptide treatments ........................................................................ 59 
3.10 Whole-cell LTP in organotypic hippocampal slices ................... 59 
3.11 Immunohistochemistry ............................................................... 61 
3.12 Confocal microscopy .................................................................. 62 
3.13 Statistical analysis ...................................................................... 63 	  
 
PROJECT 1:  ...................................................................................... 64 	  
	   4	  
4. RESULTS ....................................................................................... 64 	   	  
4.1Early Impairment of insulin signalling cascade in the parietal 
cortex of beagles .............................................................................. 64 
4.2 Reduced BVR-A activation in the parietal cortex of aged 
beagles  ............................................................................................ 67 
4.3 Reduced BVR-A activation is associated with an increased 
CKI-mediated phosphorylation of BACE1 in the parietal cortex ... 70 
4.4 Increased BACE1 Ser phosphorylation is associated with 
increased Aβ levels in the parietal cortex ........................................ 76 
4.5 Insulin resistance-associated BVR-A impairment promotes the 
increase of Aβ production by favoring the CKI-mediated Ser 
phosphorylation of BACE1 ............................................................. 78 	  
5. DISCUSSION ................................................................................. 81 	  	  
PROJECT 2  ....................................................................................... 89 	  
6. RESULTS ....................................................................................... 89 	  
6.1 Intranasal insulin administration improves short-term learning 
and memory in 6- and 12-month-old 3xTg-AD mice. .................... 89 
6.2 Intranasal insulin administration ameliorates the depressiove-
like behaviour in 3xTg-AD mice. .................................................. 91 
	   5	  
6.3 Intranasal insulin administration prevents the impairment of 
BVR-A and the early dysfunction of the insulin signalling 
cascade in adult 3×Tg-AD mice at 6 months of age. .................... 93 
6.4 Intranasal insulin administration recovers BVR-A activation 
and prevents the onset of brain insulin resistance in aged 3×Tg-
AD mice at 12 months of age. ..................................................... 100 
6.5 BVR-A is required for the correct transduction of the insulin 
signalling cascade in vitro. .......................................................... 105 
6.6 Amelioration of insulin signalling activation is associated with 
reduced oxidative stress levels and AD neurpathologial 
markers in the hippocampus and cortex of INI-treated 3xTg-
AD mice.  .................................................................................... 112 	  
7. DISCUSSION ............................................................................... 115 	  	  
8. CONCLUSIONS .......................................................................... 121     
 	  
9. REFERENCES ............................................................................. 123 	  	  
10. APPENDIX ................................................................................ 162 
 	  	  	  
	   6	  
List of Abbreviations: 
 
3-NT: 3-nitrotyrosine 
4E-BP: 4E-binding protein 
AD: Alzheimer disease 
AICD: amyloid intracellular C-terminal fragments 
aMCI: amnistic MCI 
AP-1: Activator protein 1  
APLP1/2: APP-like protein 1/2 
ApoE4: ApolipoproteinE-4 
APP: amyloid precursor protein 
Aβ: amyloid b (Ab)-peptide 
BACE-1: beta-site amyloid precursor protein-cleaving enzyme 1 
BBB: Blood brain barrier  
BIR: Brain Insulin resistance 
BR: Bilirubin 
BV: Biliverdin 
BVR-A: Biliverdin reductase-A 
CK1: casein kinase 1 
CNS: Central Nervous System 
CSF: cerebrospinal fluid 
CTF: carboxyl terminal fragment 
DIAD: Dominant inherited AD 
	   7	  
DM: diabetes mellitus  
DNPH: dinitrophenylhydrazine 
EAD: early AD 
ER: endoplasmic reticulum 
ERK1/2: Signal-regulated kinases 1/2 
FAD: Familial AD 
FOXO3: Forkhead box O3 
GDP: guanosine diphosphate 
GLUT4: glucose transporter type 4 
GPX: Glutathione peroxidase 
GRB2: growth factor receptor-bound protein 2 
GSK3β: glycogen synthase kinase 3β 
GTP: guanosine triphosphate 
H2O2: hydrogen peroxide 
HNE: 4-hydroxy-2-nonenal 
HO-1: Heme oxygenase 1 
HO•: hydroxyl radical: 
IAPP: islet amyloid polypeptide 
IGF-1R: Insulin-like growth factor receptors 
INI: Intranasal insulin  
IR: Insulin receptor  
IRS: Insulin receptor substrate  
JNK1: c-Jun N-terminal kinases 
LAD: Late-stage AD 
	   8	  
MAPK: Mitogen-activated protein kinases 
MCI: mild cognitive impairment 
mTOR: mammalian target of rapamycin 
NFTs: neurofibrillary tangles 
NO•: nitric oxide 
O2−•: superoxide radical anion 
ONOO−: peroxynitrite 
OS: Oxidative stress 
P70S6K: Ribosomal protein S6 kinase beta-1 
PC: protein carbonyls 
PCAD: preclinical AD 
PDK1: phosphoinositide-dependent kinase 1 
PH: pleckstrin homologe 
PI3K: Fosfoinositide 3-chinasi 
PIKK: phosphatidylinositol 3-kinase-related kinase protein 
PIP3: phosphatidylinositol (3,4,5)-triphosphate 
PKB: protein kinase B /AKT 
PKC: protein kinase C 
PKR: protein kinase R 
PS1/PS2: Presenil-1/2 
PTB: phosphotyrosine-binding 
PTEN: phosphatase and tensin homolog 
PUFAs: Polynsatured fatty acid  
rER: rough endoplasmic reticulum 
	   9	  
RNS: Reactive nitrogen species  
ROS: Reactive oxygen species 
SAD: Sporadic AD 
sAPPα/β: soluble APP α/β 
SH2: Src Homology 2 
SHIP: SH2 domain containing inositol-5-phosphatase  
siRNA: Small-interfering RNA 
SOCS: suppressor of cytokine singalling  
SOD1: Superoxide dismutase 
SOS: Son of seven less 
SPs: senile plaques 
SRP: signal recognition particles 
T2D: type 2 diabetes 
TGN: Trans-Golgi network  
TNFα: Tumor necrosis factor α 
 
  
	   10	  
1. INTRODUCTION  
 
1. Alzheimer’s Disease 
 
In 1907, Aloïs Alzheimer related in the article “On an unusual Illness 
of the Cerebral Cortex” the uncommon case of a 51-year-old patient who was 
suffering from memory loss, disorientation, hallucinations and cognitive 
impairment. After the death of the patient, post mortem examination showed 
an atrophic brain with “striking changes of the neurofibrils” and “minute 
military foci” caused by the “deposition of a special substance in the cortex” 
[1]. One century later, this “unusual illness” named Alzheimer’s disease 
(AD) has become the most widespread neurodegenerative disease whose 
etiology is still unknown [2]. 
 
 AD is an age-related neurodegenerative disorder and is the most 
common form of dementia in the elderly people, accounting for 50% to 70% 
of cases. Approximately 10–30% in the population over 65 years of age, 15-
20% over age 75, and 25-50% over age 85 are affected by dementia. The 
major prevalence is in Asia (22.9 million people) while Europe and the 
Americas account for 10.5 and 9.4 million people, respectively [3]. 
According to the World Alzheimer Report, 46.8 million people worldwide 
are afflicted with AD; this number is expected to increase to 131 million 
people by the year 2050 [4, 5]. 
It is characterized by a progressive deterioration of cognitive 
functions that can be linked to a significant reduction of the volume of the 
brain in AD patients as compared to healthy patients. The atrophy results 
from the degeneration of synapses and the death of neurons, in particular in 
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hippocampus, the brain region playing a role in memory and spatial 
orientation. The age is the highest risk factor for AD, the risk of developing 
the disease reaching 50% for individuals beyond age 85 [3]. Interesting, 
because of higher life expectancy and the decrease in estrogen levels due to 
menopause, women are more susceptible than men to develop AD [6].  
Pathologically, apart a loss of synapses, AD is identify by an increase 
in the number of extracellular amyloid beta-peptide (Aβ)-rich senile plaques 
(SPs), derived from the cleavage of amyloid precursor protein (APP), and an 
increase in intracellular neurofibrillary tangles (NFTs) composed of 
aggregated hyper phosphorylated Tau, a microtubule stabilizing protein [7, 
8]. 
There are two major forms of AD: the sporadic (SAD) and the 
familial (FAD). Most patients with Alzheimer’s disease (>95%) have the 
SAD, which is characterized by a late onset (80–90 years of age), and it is the 
consequence of the failure to clear Aβ peptide from the interstices of the 
brain. A small subset (<10%) of AD cases have autosomal dominant 
inherited Alzheimer’s disease (DIAD) and have an early age of onset (mean 
age of ~45 years). Individuals living with Down’s syndrome (also called 
trisomy 21) have an increased risk of early-onset AD because they carry an 
extra copy of chromosome 21 in which is located the gene responsible for 
APP formation [9]. Mutations of several genes encoding APP, PS1 and PS2, 
which cause overproduction or formation of an aberrant form of Aβ, have 
been found to cause mainly early-onset AD [10, 11], while apolipoprotein E4 
(ApoE4) (involved in Aβ clearance) is considered as being the most common 
high genetic risk factor for late-onset AD [12].    
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From a clinical point of view, AD is characterized by a decline in 
episodic memory that is often mistaken for normal cognitive deficiencies due 
to aging. Because the pathology remains hidden within the brain tissue and 
the high presence of co-morbidities, such as cerebrovascular disease and 
hippocampal sclerosis, clinical diagnosis remains inherently error prone and 
subjective. The National Institute of Neurological and Communicative 
Disorders and Stroke in conjunction with the Alzheimer's Disease and 
Related Disorders Association (NINCDS-ADRDA) have established valid 
clinical and research criteria, based on the use of conventional clinical, 
laboratory, and imaging techniques, for the diagnosis of probable, and 
possible AD [13]. Even if, an accuracy diagnosis during life is as high as 
85% due to modern imaging and laboratory techniques, a definite diagnosis 
of AD can only be made by biopsy or with specimens obtained at an autopsy 
[14]. 
The progression of this disease can be stratified into four main stages: 
preclinical AD (PCAD), mild cognitive impairment (MCI), early AD (EAD) 
and late-stage AD (LAD). PCAD is defined as the potential stage of AD in 
which the patient presents as a fully functional individual in cognitive exams, 
yet the growing pathology within the brain tissue is present [15]. MCI has 
been described as being the transition stage between normal cognition and 
EAD, and is subdivided intro both amnestic MCI (aMCI) and non-amnestic 
MCI [16]. Pathologically, each stage differs in that both amyloid plaques and 
NFTs increase in distribution and density from MCI to LAD.   
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1.1 Amyloid precursor protein  
 
APP is a member of a family of related proteins that includes APP-
like protein 1 (APLP1) and 2 (APLP2). They are single-pass transmembrane 
proteins with a large extracellular domain and a short cytoplasmatic region 
that undergo similar processing. The Aβ domain is unique to the APP, though 
the family shares several other conserved domain such as the E1 and E2 
domains in the extracellular sequence [17]. Although the native biological 
role of this protein is obvious of interest to AD, APP is involved in several 
physiological functions such as neuritis outgrowth, synaptogenesis, neuronal 
protein trafficking, cell adhesion and calcium metabolism [18, 19].  
The human APP gene, located on chromosome 21, was first identified 
in 1987 [20] and 8 isoforms arising from alternative splicing of that. The 3 
isoforms most common are: APP695, which is expressed predominantly in 
the CNS, APP751 and APP770, which are more ubiquitously expressed. 
Mutations in critical regions of APP, including the region that generates Aβ, 
are causative of the hereditary form of familial AD and a related condition of 
hereditary cerebral amyloid angiopathy [21, 22].   
Full-length APP is produced in large quantities in neurons and is 
metabolized very rapidly. It is synthesized in the endoplasmatic reticulum 
(ER) and then transported through the Golgi apparatus to the trans-Golgi-
network (TGN), where can be transported to the cell surface or directly to an 
endosomal compartment. Crucial steps in APP processing occur at the cell 
surface and in the TGN. Sequential secretase cleavage of the APP occurs by 
two pathways: Non-amyloidogenic processing and Amyloidogenic 
processing. Both processes generate soluble ectodomains (sAPPα and 
sAPPβ) and identical amyloid intracellular C-terminal fragments (AICD). 
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Although under physiological conditions, the majority (≈ 90%) of APP 
processing undergoes non-amyloidogenic processing via α-secretase 
cleavage within the Aß domain, changes in the balance between 
amyloidogenic and non-amyloidogenic APP processing has the potential to 
affect dramatically Aß generation and accumulation.  
Over to secretase cleavage, APP can be cleaved by caspases 
(predominantly caspase-3) at position Asp664 within the cytoplasmic tail 
during apoptosis to generate a potentially cytotoxic peptide containing the 
last 31 amino acids of APP (called C31). Additional γ-cleavage generates the 
fragment containing the region between γ – and caspase-cleavage sites called 
JCasp [23, 24], which has been reported to play a minor role in cytotoxicity.  
Cleavage of APP by α-secretase precludes Aß generation, as the 
cleavage site is within the Aß domain, and releases a large soluble 
ectodomain of APP (sAPPα) and an 83-residue carboxy-terminal fragment 
(APP C-83). Α-secretase is a zinco metalloproteinase, which cleaves APP 
primarily at the plasma membrane. Several members of the ADAM (a 
disintegrin and metalloproteinase) family possess α-secretase-like activity 
and three of them have been suggested as the α-secretase:  ADAM9, 
ADAM10 and ADAM17. sAPPα has an important role in neuronal 
plasticity/survival and is protective against excitotoxicity. Moreover, it 
regulates neuronal stem cell proliferation and is important for early CNS 
development. The CFT, once formed, is cleaved by γ-secretase to generate 
p83 and the APP intracellular domain (AICD). The p83 fragment is rapidly 
degraded and widely believed to possess non-important function [25].  
The first step in Aß generation is the cleavage of APP by beta-site 
amyloid precursor protein-cleaving enzyme 1 (BACE1), a β-secretase [26].  
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ß-cleavage releases a soluble APPß fragment (sAPPß) and a 99-residue 
carboxy-terminal fragment (APP C-99). Although sAPPß only differs from 
sAPPα by lacking the Aß1-16 region at its carboxyl-terminus and it was 
reported to function as a death receptor 6 ligand, mediate axonal pruning and 
neuronal cell death [27]. After the ß-cleavage the ßCTF remain membrane-
associated and will be further cleaved by γ-secretase. Since these APP CTF is 
intermediate products, their functions have been less characterized. However, 
overexpression of APP ßCTF was found to be cytotoxic and cause neuronal 
degeneration, perhaps by perturbing APP signal transduction [28]. γ-cleavage 
can yield both Aß40 , the majority species of Aß in the brain, and Aß42, as 
well as release the intracellular domain of APP (AICD).  
 
 
Figure 1. Schematic representation of APP processing. The APP processing occurs in two 
distinct pathways: non-amyloidogenic and amyloidogenic.  The amyloidogenic pathway 
involves the sequential cleavage of APP by β-secretase, which releases a sAPPβ and the β-
CTF. This is cleaved by γ-secretase, generating AICD and releasing Aβ. In the non-
amyloidogenic pathway APP are cleaved at the α-secretase site within the Aβ-domain 
releasing sAPPα and the α-CTF. Proteolytic cleavage of α-CTF by γ-secretase releases AICD 
and p3 fragment. 
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1.1.1 BACE1   
 
In 1999-2000, several groups identified BACE1 (called Asp2 or 
memapsin 2) as the major ß-secretase. BACE1 has two aspartic protease 
active site motifs, DTGS (residues 93-96) and DSGT (residues 289-292), and 
mutation of either aspartic acid renders the enzyme inactive [29]. Like other 
aspartic proteases, BACE1, has an N-terminal signal sequence (residues 1-
21) and a pro-peptide domain (residues 22-45) that are removed by post-
translational modification [30]. Moreover, it has a single transmembrane 
domain near its C-terminus  (residues 455-480) and a palmitoylated 
cytoplasmic tail [31, 32].  
The cell biology of BACE1 was investigated in order to further 
understand BACE1 regulation and to identify other potential therapeutic 
targets in the ß-secretase pathway. It is initially synthesized in the 
endoplasmic reticulum (ER) as an immature precursor protein (proBACE1) 
with a molecular weight of ≈ 60 kDa. ProBACE1 is short–lived and 
undergoes rapid maturation, in the Golgi,  into a 70 kDa form, which 
involves the addition of complex carbohydrates and removal of the 
propeptide domain [33].  The majority of BACE1 molecules are localized 
within Golgi and endosomal compartments, where they co-localize with 
ßAPP [29, 34].  The acidic pH optimum of BACE1 indicates that it is 
predominantly active within late Golgi compartments and/or 
endosomes/lysosomes. This is consistent with previous findings 
demonstrating that ß-secretase cleavage of ßAPP can occur in all of these 
acidic compartments [35, 36].  
Interesting, it has been reported that BACE1 is re-internalized from 
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the cell surfaces to early endosomes and can recycle back to the cell surface, 
where is available to cleave APP again. The intracellular trafficking is largely 
controlled by a dileucin motif in the cytoplasmic tail of BACE1 [37]. This 
signal is located close to a negatively charged domain, which contains a 
potential phosphorylation site. BACE1 is phosphorylated within its C-
terminal and that the biological function of BACE1 phosphorylation resides 
in the regulation of the retrieval of re-internalized BACE1 from endosomes 
[38].  Walter et colleagues identified a single phosphorylation site on serine 
residue 498 in the C-terminal domain of BACE1 and that casein kinase 1 
(CK1) can phosphorylate BACE1 at the serine residue [38]. The 
phosphorylation site, which is preceded by a stretch of acidic amino acid 
residues, represents a canonical recognition motif for CK1, but not for 
glycogen synthase kinase 3β or cyclin-dependent kinases. Even if the 
mechanisms through which this kinase influences BACE1 trafficking is still 
unknown, we cannot exclude the possibility that the phosphorylation may 
have subtle effects on βAPP processing and may be altered during the 
pathogenesis of AD. 
CK1 consists of a family of eight genes, which appear to function as 
monomeric enzymes: α, γ1, γ2, γ3, δ, ε1, ε2, and ε3, but only CKIα, CKIδ 
and CKIε are elevated in human AD hippocampus. Family members contain 
a highly conserved N-terminal catalytic domain of ≈290 residues coupled to a 
variable C-terminal region that ranges in size from 40 to 180 aa. It is present 
in both the cytosol and the nucleus but the C-terminal region of that promote 
differential subcellular localization of individual isoforms (e.g., cellular 
membrane versus cytoplasm) [39, 40]. A number of proteins have been found 
to interact with CK1 isoforms in several tissues resulting in its targeting to 
specific signaling pathways [41, 42].  
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Moreover, several lines of evidence suggest that constitutively active 
CK1ε increases the formation of Aβ. The mechanism by which CK1ε activity 
leads to the regulation of Aβ formation is still unknown [43]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Intracellular trafficking of BACE1. BACE1 are internalized from the cell 
surface in the early endosomes. From the early endosomes, the intracellular trafficking 
itineraries of BACE1 is trafficked to the late endosome/lysosome and then it is transported to 
the recycling endosomes before being recycling back to the cell surface.  
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1.1.2  Amyloid beta function   
 
The toxic effects of Aß have been explored widely but a few studies 
in the past decade have also highlighted its physiological roles in maintaining 
a healthy nervous system in a concentration-dependent manner [44].  The 
physiological processes positively influenced by Aß are neurogenesis, 
synaptic plasticity, memory formation, calcium homeostasis, metal 
sequestration and antioxidant properties [45].  
There are two main toxic species of Aß, Aß40 and Aß42. The last one 
has two extra hydrophobic amino acids compared to Aß40, which promotes 
greater fibrilar formation in Aß42 and is known to be more toxic. Once Aß is 
produced, individual amyloid peptides, (Aß42 in particular) spontaneously 
self-aggregates to form small multiple coexisting physical forms. One forms 
consists of oligomers (2 to 6 peptides), which coalesce into intermediate 
assemblies [46]. ß-amyloid can also grow into fibrils, which arrange 
themselves into ß-plated sheets to form the insoluble fibers of advanced 
amyloid plaque. Soluble oligomers and intermediate amyloids are the most 
neurotoxic forms of Aß. Although the majority of Aß is secreted out of the 
cells, it can be generated in several subcellular compartments, such as the 
ER, Golgi/TGN, and endosome/lysosome. In addition, extracellular Aß can 
be internalized in the cell for degradation.   
However, since Aβ has been found in healthy brain in soluble form 
but in aggregated form in AD patient brain [47], a hypothesis has been 
proposed to explain the formation of the senile plaques. The amyloid cascade 
hypothesis formulated in the early 1990s [48] has become a dominant model 
for AD pathogenesis [49]. The hypothesis proposed that an abnormal 
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extracellular increase of Aβ levels in brain could lead to Aβ aggregation into 
β-sheet rich structures. Aggregation starts with the formation of oligomers 
species that are reorganized into protofibrils and fibrils, found in amyloid 
plaques. Oligomers accumulated in AD patient brains are suggested to be the 
more toxic species for cells [50, 51], as they can in particular permeabilize 
cellular membranes, thus initiating a series of events leading to cell 
dysfunction and death .     
                                             
1.2 Oxidative damage 
 
Accumulation of Aβ impairs mitochondrial redox activity, increases 
the generation of reactive oxygen (ROS) and reactive nitrogen species 
(RNS). In AD and in the normal aging brain, they cause considerable 
oxidative stress (OS), which in turn contribute to lipid and protein damage 
[52, 53]. Mounting evidence suggests an important role played by biometals 
including iron, zinc and copper in Aβ and neurodegeneration [54]. In 
concordance with those findings, there are high affinity binding sites for 
copper and zinc on the N-terminal metal-binding domains of Aβ and its 
precursor APP while copper is a potent mediator of the highly reactive 
hydroxyl radical (OH•), and consequently contributes to the increase of 
oxidative stress characteristic of AD brain according to the high 
concentration of copper found in amyloid plaques [55]. This seems to be 
associated with the length of Aβ fragments, with Aβ42 being more toxic than 
Aβ40 and the most likely candidate to generate hydrogen peroxide and other 
ROS. 	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OS is induced by an imbalance in the redox state, involving the 
generation of excess reactive oxygen species (ROS) or the dysfunction of the 
antioxidant system. A major protective system of the cell is the “team” of 
antioxidant enzymes such as superoxide dismutase (SOD), glutathione 
peroxidase (GPx), glutaredoxins, thioredoxins and catalase. A reduction or a 
loss of function of the antioxidant enzymes, as indexed by decreased specific 
activity, has been reported in AD [56]. Proteins are highly susceptible to 
oxidative damage that inevitably affects secondary and tertiary structure 
resulting in irreversible modification of protein shape and, consequently, 
function. These modifications include dissociation of subunits, unfolding, 
exposure of hydrophobic residues, aggregation and backbone fragmentation 
among others [57] . 
There are three major indices of protein oxidation that are detectable 
by standard methods: protein carbonylation (PC), protein nitration (3-NT) 
and protein bound-4 hydroxynonenal (HNE). 
Protein carbonyl groups are generated from the direct oxidation by 
ROS of various side chains of amino acid residues (Lys, Arg, Pro, Thr, His 
and others) by the extraction of hydrogen atoms by alpha carbons and by 
cleavage of the peptide chain. This global oxidation process is referred to  
“primary protein carbonylation”, a product that could be detected by the 
reaction with 2,4-dinitrophenylhydrazine (DNPH), forming DNP-hydrazones 
[58].  
Protein tyrosine nitration (3-NT) is a well-characterized chemical 
modification and normally is considered an irreversible form of protein 
damage, and therefore a robust biomarker of nitrosative stress [59]. Protein 
nitration occurs following formation of peroxynitrite (ONOO−) from 
superoxide (O2•−) and nitric oxide (NO•).  
Lipid peroxidation is one of the main events causing redox imbalance 
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and subsequent build-up of oxidative damage within the cell. Lipid 
peroxidation is able to damage directly membranes, because ROS attack 
polyunsaturated fatty acids (PUFA) in the lipid bilayer. Neuronal membranes 
are particularly rich in PUFAs, that are broken down and release elevated 
levels of reactive electrophilic aldehydes, able to bind covalently proteins by 
forming adducts with specific amino acids. According to a number of factors, 
such as acyl chain length and degree of unsaturation, the lipid hydroperoxide 
that is formed by reaction of a carbon radical with oxygen, can form 
malondialde-hyde, 4-hydroxy-2- trans-nonenal (HNE) and acrolein, among 
other products of lipid peroxidation. Among these, HNE is a highly reactive 
and is produced primarily in the brain via lipid peroxidation of arachidonic 
acid, highly abundant omega- 6 PUFA components of neuronal membranes.  
Increased damage to proteins, detected using proteomics approaches, 
show that specific proteins are modified by OS and that this alteration can 
contribute to the impairment of several key pathogenic pathways [60]. 
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2. Insulin: structure and biosynthesis   
 
Until the end of the 1950s, insulin was considered only as a hormone 
secreted by the β cells of the pancreatic islets of Langerhans and maintains 
normal blood glucose levels facilitating the absorption of cellular glucose, 
regulating the metabolism of carbohydrates, lipids and proteins and 
promoting cell division and growth through its mitogenic effects.  
Insulin consists of two polypeptide chains: α, consists of 21 amino 
acids, and β, consists of 30 amino acids. The two chains are linked together 
by two disulfide bonds; an additional disulfide is formed within the α chain.  
The secreted insulin consists of 51 amino acids with a molecular weight of 
5.8 kDa. However, the insulin gene encodes a 110-amino acid precursor 
known as preproinsulin. As with other secreted proteins, preproinsulin 
contains a hydrophobic N-terminal signal peptide, which interacts with 
cytosolic ribonucleoprotein signal recognition particles (SRP) [61]. SRP 
facilitates preproinsulin translocation across the rough endoplasmic reticulum 
(rER) membrane into the lumen. This process occurs via the peptide-
conducting channel, where the signal peptide from preproinsulin is cleaved 
by a signal peptidase to yield proinsulin [62]. In the ER the proinsulin, after a 
conformation changing is transported to the trans-Golgi network (TGN) 
where it enters immature secretary vesicles and it is cleaved to yield insulin 
and C-peptide. Insulin and C-peptide are then stored in these secretory 
granules together with islet amyloid polypeptide (IAPP or amylin) and other 
less abundant β-cell secretary products [63, 64].  
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The β-cells respond to many nutrients in the blood circulation, 
including glucose, other monosaccharaides, amino acids and fatty acids. 
Glucose is the primary stimuli for insulin release in some animal species, 
because it is a principal food component and can accumulate immediately 
after food ingestion.  
 
 
Figure 3. Insulin structure and biosynthesis  
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2.1 Cerebral Insulin 
 
In the late 1970s, the central nervous system (CNS) was not 
considered an insulin-dependent tissue, but now it is well known that insulin 
plays a major physiologic role in this tissue and its disturbances, being 
involved in certain neurodegenerative states, such as Alzheimer’s disease 
(AD). The presence of insulin in the brain was first detected by Havrankova, 
who used radioimmunoassay to determine high levels of insulin in brain 
extracts [65]. Likewise, they reported that insulin content in the brain was 
independent of the peripheral insulin, since circulating insulin levels had no 
effect on the brain’s insulin concentration [66].  
The notion that insulin could cross the Blood brain barrier (BBB) was 
first suggested by Margolis and Altszuler, who showed that insulin levels in 
the Cerebrospinal fluid (CSF) of rats increased slightly after peripheral 
infusions of this hormone suggesting that insulin crossed the BBB possibly 
by means of a saturable transport system [67].  These results were later 
confirmed in dogs after the intravenous administration of insulin [68]. They 
found a large, rapid increase in blood insulin, but a relatively small increase 
in the hormone in the CSF. These findings confirmed a non-linear correlation 
between plasma and CSF levels of insulin, providing the first evidence for a 
saturable transport system for this hormone from blood to the brain. 
Although there is no direct evidence on whether the insulin transport system 
and the Insulin receptor (IR) are the same protein, this seems to be widely 
assumed, as they have similar physicochemical properties (saturability, 
specificity, affinity, immune neutralization, cooperative interactions, and 
kinetics of dissociation) [67, 69]. On the other hand, differences in the 
activity of the BBB transporter system may be responding to regional 
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differences in insulin permeability, and also to the hormone concentration, 
recording the highest values in the pons, medulla, and hypothalamus, and the 
lowest in the occipital cortex and thalamus [70]. This insulin transport may 
be regulated by multiple factors, such as glucocorticoids, or by several 
pathophysiological situations, such as obesity, diabetes mellitus (DM), AD or 
the physiological aging process [71] . 
Evidence also exists that insulin can be produced de novo in brain 
regions such as the hippocampus, prefrontal cortex, olfactory bulb and 
entorhinal cortex [65, 72, 73]. While the significance of this evidence is still 
debated, recent studies show that functional insulin signaling components in 
forebrain regions may exert a neuroprotective role in areas responsible for 
various functions of memory [74, 75].  
 
 
2.1.1 Mechanisms of insulin signaling transduction in the 
brain 
  
IR is tetrameric glycoproteins that belong to the receptor tyrosine 
kinase (Tyr) well studied with regard to its function in the regulation of 
peripheral glucose metabolism. Although expression of the insulin receptor 
in the brain was discovered decades ago [65, 76], insulin receptor function in 
this classic 'insulin-insensitive' organ remains largely unknown. Recent 
studies in neuronal cell culture suggest that insulin receptor signaling 
regulates several neuronal functions, including spine density and neurite 
growth [77, 78]. It is composed of two ligand-binding sites, disulfide-linked 
extracellular α subunits, which are linked by disulfide bonds to two 
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membrane-spanning β subunits. The α subunit is predominantly hydrophilic 
in nature, lacks membrane anchor regions, and contains 15 potential N-
glycosylation sites and 37 cysteine residues. The β subunit contains a portion 
that is extracellular, a portion that comprises the transmembrane region of the 
receptor, and a portion that is intracellular, and which possess inherent 
tyrosine-protein-kinase activity [79]. Interestingly, two different isoforms of 
IR have been found in mammalian: IR-B (the longer isoform) is the most 
prominent isoform in classical insulin-sensitive tissues, skeletal muscle, 
adipose tissue, and liver; and IR-A prominent in the brain [80, 81].  These 
receptors are highly abundant in all the cerebral areas, especially in the 
hypothalamus, cerebellum, hippocampus and cerebral cortex and striatum. 
Concerning intracellular localization, this receptors are more present 
in neurons (with high protein expression in cell bodies and synapses) than in 
glial cells and the levels of these decrease with the age, suggesting an 
involvement in the aging [82, 83].   
Once bound to α subunits of neuronal IR, insulin promotes auto 
phosphorylation of the β subunits at Tyr residues 1158,1162 and 1163 
triggering its intrinsic Tyr kinase activity and phosphorylating insulin 
receptor substrate (IRS) docking proteins (IRS1-4) at Tyr residues [84, 85], 
which initiate divergent signal transduction pathways [86]. Likewise, 
following the binding of insulin, aggregated IRs are rapidly internalized into 
the cell by a process that at least in part involves coated pits and vesicles 
[87]. It has been suggested that aggregation or internalization could be 
essential for insulin signaling [88]. The internalized IRs can then be degraded 
or recycled back to the cell membrane.  In literature are described 6 isoforms 
of IRSs (IRS1, IRS2, IRS3, IRS4, IRS5 and IRS6) but the most insulin 
responses are mediated by IRS1 and IRS2. IRS1 controls body growth and 
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peripheral insulin action, while IRS2 regulates brain growth, body weight 
control, glucose homeostasis, and female fertility [84]. IRS proteins are 
composed of an NH2-terminal pleckstrin homology (PH) domain adjacent to 
a phosphotyrosine-binding (PTB) domain, and followed by a tail containing 
numerous tyrosine and Ser/Thr phosphorylation sites (75). The Tyr 
phosphorylation sites coordinate down-stream signaling cascades by binding 
the SH2 domains present in common effector proteins, including enzymes 
(the phospho- inositide 3-kinase, PI3K; the phosphatase SHP2; or the 
tyrosine- kinase Fyn) or adapters (SOCS1, SOCS-3, GRB2, and others) [84, 
89]. By contrast, the specific serine phosphorylation of the IRS1/2 by the c-
Jun N-terminal kinase (JNK1) and other protein kinases inhibits insulin-
stimulated tyrosine phosphorylation, which correlates closely with insulin 
resistance (76).  
Two major cellular signaling pathways can be activated by the kinase 
activity of insulin receptor are: phosphoinositide-3 kinase (PI3K)/Akt and the 
Ras/mitogen-activated protein kinase (MAPK) pathways. These cascades 
regulate several cellular processes, such as gene expression, protein 
synthesis, vesicle trafficking, lipid and protein metabolism, cell growth and 
differentiation [90, 91]. The activation of the two pathways not necessarily 
occur simultaneously, especially in pathophysiological conditions, where one 
pathway can prevail over the other [92].  
There are more proteins that can act a negative regulators strictly 
control on the intensity and duration of the insulin signal. Among these we 
know same phosphatases: (i) LAR and PTP1B which dephosphorylate the 
Tyr residues of IR and IRS, (ii) PP2A, PP2B and PP2C which regulate the 
activity of Akt and ERK by the Ser/Thr residues and (iii) PTEN and SHIP2 
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regulate the activity of PIP3, antagonizing the PI3K/AKT pathway [93]. 
Interesting is the inhibitory modulation obtains through the phosphorylation 
of IRS on Ser/Thr residues by same kinases like PKC, JNK, IKK, MAPK and 
AKT. In particular AKT mediates the signal through the activation of mTOR, 
which inactive IRS.  In details, mTOR-mediated inhibitory phosphorylation 
of IRS1 on a serine residue uncouples PI3K/Akt axis from insulin and IGF-1 
receptor signals. Therefore, potentially leading to the development of insulin 
resistance. Other proteins, such as JNK or inflammatory components (e.g. 
TNFα), can switch off PI3K/Akt axis regulating IRS1 activity [94, 95]. 
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Figure 4. Mechanisms of insulin signalling in the brain. Under normal conditions binding 
of insulin to IR promotes its activation through IR dimerization and autophosphorylation of 
specific Tyr residues. Stimulation of IR kinase activity is then followed by Tyr 
phosphorylation of a variety of endogenous substrates, including IRS-1. These events lead 
the activation of multiple signaling pathway required for insulin’s pleiotropic action, 
including: (i) PI3K/AKT axis and (ii) MAPK cascade. The first one has reached the crucial 
point in the activation of AKT, the main node of the signal cascade. It is a serine / threonine 
kinase that has several molecular targets: e.i. GSK3-β and mTOR. The second pathway sees 
the final activation of MAPK that culminate in the activation of several transcription factors 
that control gene expression. Insulin signalling is regulated by the action of several 
molecules, such as phosphatases (PP2A, PP2C, PTEN, SHIP2, PTB1B) which 
dephosphorylate IRS, IR, PKC, ERK, PIP3 and AKT; serine/threonine kinases that 
determine the inactivativeation of IRS1 and the stress kinases such as JNK, IKK and MAPK, 
along with PKC and S6K activated by mTOR.  
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2.1.1.1  PI3K/Akt axis 
 
After binding of the p85 SH2 domain to the phosphorylated Tyr of 
active IRS, PI3K becomes active and p110 inhibition is relieved, allowing 
translocation of active PI3K to plasma membrane and subsequent 
transformation of phosphatidylinositol 4,5-bisphosphate (PIP2) to PI-3,4,5-
trisphosphate (PIP3). All of this pathway is negatively regulated by 
phosphatase and tensin homolog, PTEN [96]. Then, PIP3 bind and recruit 
from the membrane, phosphoinositide- dependent kinase-1 (PDK-1), 
determining the activation. Consequently, activated PDK-1 in turn recruit and 
active form the plasma membrane some protein kinase: protein kinase C 
(PKC) and protein kinase B (PKB or Akt) [97] through the phosphorylation 
of Thr-308 and Ser-473 residues [98, 99]. Once activated, AKT, detaches 
from plasma membrane and translocate into cytosol and nucleus [99], where 
it phosphorylates target proteins at Ser and Thr residues, thus regulating 
numerous processes [100] : (i) activation of mTOR, which is associated with 
the regulation of genes involved in the control of protein synthesis, cell 
growth and neuronal glucose metabolism; (ii) inhibition  of FoxO3 (Forkhead 
box O), which cause the block of nuclear translocation of FoxO3 and its 
subsequent deleterious targeting of nuclear genes, thus promoting 
hippocampal and cerebrellar granular neuronal survival [101]; (iii) inhibition 
of several proapoptotic proteins such as GSK-3β , caspasi-9 and Bad; and 
(iv) activation of CREB (cAMP – responsive element-binding protein).  
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Once the activation of mTOR by AKT, several phosphorylates 
components of the protein synthesis machinery, including ribosomal S6 
kinase 1 (S6K1), and the translation inhibitor eukaryotic translation initiation 
factor 4E-binding protein (4E-BP) are activated by it [102, 103]. S6K1 
presents two different isoforms, the p70 (p70S6K) mainly cytoplasmic and 
the p85 (p85S6K) with 23 additional that allows its targeting to the nucleus 
[104]. 4E-BP exists in three isoforms (1, 2, and 3) that have similar functions 
but differs in their tissue distribution. 4E-BP3 expression is limited to few 
tissues, and is excluded from the nervous system while both 4E- BP 1 and 2 
are expressed in nervous tissues but 4E-BP2 is the major isoform [105].  
GSK-3β, Ser/Thr protein kinase, is inactive by Akt through a 
phosphorylation at the N-terminal Ser9, initiating multiple physiologic 
effects [106, 107]. GSK-3β is negatively regulated also by PKC and c-AMP-
dependent protein kinase (PKA) (which are also activated by insulin) [108]. 
Depending on the cellular context, GSK-3β can be targeted to different 
intracellular locations (e.g., cytosol, mitochondria, or nucleus) to easily 
access its substrates: active GSK-3β (Ser9 dephosphorylated) appears mostly 
in nuclei, mitochondria, and membrane lipid rafts (detergent-resistant plasma 
membrane micro domains involved in signal transduction), while inactive 
GSK-3β is mostly cytosolic [109]. Besides Ser9 dephosphorylation, GSK- 3β 
can be also activated by phosphorylation at Tyr216, and, although this 
mechanism remains unclear, changes in intracellular Ca2+ or Fyn (a member 
of the Src Tyr kinase family) appear to be involved [110, 111]. The inhibition 
of GSK3β, occurring after PI3K inhibition, has been described to prevent 
apoptosis, while overexpression of a constitutively active GSK-3β resulted in 
PC12 cell death [112] .  
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Figure 5. PI3K/AKT axis. mTOR and insulin signaling network. Growth factors, such as 
insulin, and nutrients, such as glucose, bind to membrane receptors to activate class I PI3K. 
This process generates PIP3, which recruits protein kinase B (PKB/Akt) and its activator 
PDK1 (phosphoinositide-dependent kinase 1) to the plasma membrane, resulting in 
activation of PKB/Akt. Active PKB/Akt indirectly activates mTOR through inhibition of 
negative regulators [tuberous sclerosis complex (TSC1/2)] of mTOR and activating the 
mTOR activator Rheb (Ras homolog enriched in brain). mTOR phosphorylates and activates 
S6 kinase 1 (p70S6K1), that in turn promote protein translation. In addition, mTOR 
phosphorylates and inactivates eukaryotic initiation factor 4E-binding protein (4E-BP). A 
primary negative-feedback inhibitory pathway exists whereby sustained activation 
ofmTOR/p70S6K suppresses Akt activity. This mechanism acts through mTOR-mediated 
serine phosphorylation of IRS-1, to induce IRS-1 inactivation and degradation, thus 
eliminating coupling of PI3-K/Akt to the insulin and IGF-1 receptors and other activating 
receptors.  
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2.1.1.2  ERK1/2 cascade 
 
ERK1/2 forms a parallel branch to PI3K/Akt signaling. After 
phosphorylation of IR, the adapter protein SHC (Src homology-2 domain- 
containing) binds to IR and Grb2 (growth factor receptor-bound protein 2) is 
attracted to bind to SHC via its SH2 domains, thus activating the ERK1/2 
signaling pathway; SH2 domains can also bind directly the phosphorylate 
tyrosine residues of IRS. Grb2 has other domains, SH3, that interact with the 
guanine nucleotide exchange Son of Sevenless (SOS) protein, stimulating the 
exchange of GDP for GTP at Ras, which becomes active and then recruits the 
Ser/Thr kinase Raf. Subsequent activation of MEK (or MAP2K, mitogen- 
activated protein kinase kinase) leads to phosphorylation (and activation) of 
ERK1/2 on Thr and Tyr residues [113, 114], culminating in activation of 
several transcription factors that control gene expression (e.g., Ets-like 
protein-1 (Elk-1) and c-Myc) [99].  
 
2.2 Impairment of brain insulin signaling in AD  
 
  
Brain insulin resistance (BIR) can be defined as the failure of brain 
cells to respond to insulin. Mechanistically, this lack of response could be 
due to down-regulation of insulin receptors, an inability of insulin receptors 
to bind insulin or faulty activation of the insulin signalling cascade. At the 
cellular level, this dysfunction might appear as an impairment of 
neuroplasticity and neurotransmitter release in neurons, or an alteration in 
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insulin response such as decreased expression of neuronal glucose uptake 
(GLUT4) and inflammatory responses. Functionally, brain insulin resistance 
can manifest an impaired ability to regulate metabolism — in either the brain 
or periphery — or impaired cognition and mood.  
Interestingly, metabolic stress and neuroinflammation are key 
hallmarks in AD pathology [115, 116] and ample number of evidence 
suggested that the alterations in brain insulin metabolism could be a pivotal 
responsible for the progression of these neurodegenerative disease. In support 
of this hypothesis, AD patients have shown reduced brain insulin receptor 
sensitivity, hyper phosphorylation of insulin receptor and its downstream 
second messenger IRS1 and attenuated insulin expression [117, 118]. 
Reduced brain glucose metabolism has been well described in AD and 
documented as an early even in the disease progression [119, 120]. 
Moreover, post mortem studies have demonstrated striking reductions of 
genes expression encoding both insulin and insulin receptor in CNS of AD 
cases compared to aged controls [121].  
 
Interesting, defective insulin signaling accelerates Aβ production in 
the brain by enhancing the amyloidogenic processing of the APP [122] 
and also increasing Aβ aggregation through 
monosialotetrahexosylganglioside (GM1) clustering and membrane signaling 
[123]. Thus, oligomer-induced insulin resistance may create a vicious cycle 
in which oligomers upregulate their own production and aggregation by 
disrupting insulin physiological actions. Such a mechanism could account in 
part for Aβ build up in AD brains. Multiple toxic effects of Aβ may impair 
proper brain insulin signaling and trigger a feed-forward cascade that disrupts 
neuronal functions through increased cellular stress (e.g. aberrant cytosilic 
calcium, oxidative stress, ER stress). This condition, in turn, appears to 
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intensify neuronal insulin resistance and Aβ generation. Because defective 
neuronal IR/IRS1 function appears critical for the onset of AD-related 
neuronal damage, it seems likely that bolstering insulin sensitivity and 
actions could provide encouraging results in preventing/rescuing memory 
decline. Aβ oligomers, from one side, promote the down- regulation of 
plasma membrane IR [124] whereas, from the other side, lead to the 
activation of neuronal tumor necrosis factor-alpha (TNF-α) receptor and the 
aberrant activation of stress-regulated kinases (i.e. Jun N-terminal kinase 
(JNK), I kappa B kinase (IKK), and protein kinase R (PKR) [125] and 
endoplasmic reticulum (ER) stress (PKR-mediated phosphorylation of eIF2α-
P) [126], which leads to IRS1 inactivation. The above-mentioned proteins are 
all down-stream effectors shared by a number of signaling pathways (i.e. 
lipid metabolism and inflammation) and thus not exclusively related to the 
insulin signaling, although IRS1 is among their substrates [127]. Given that, 
BIR appears to be an event secondary to the activation of these kinases due to 
other mechanisms including the elevation of the oxidative/nitrosative stress 
levels [128], inflammatory processes and ER stress [125, 126].  
The onset of BIR in AD is a matter still under debate because the 
complexity of the mechanisms underlying this phenomenon.  
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Figure 6. Aberrant brain insulin signaling in AD.  
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2.2.1   Biliverdin reductase-A 
 
As mentioned previously, insulin signalling contains several 
regulatory points, which represent critical nodes [129]. Among them 
Biliverdin reductase-A (BVR-A) has an important role in the modulation of 
this pathway [130]. BVR-A is one of the two forms of Biliverdin reductase 
(BVR).  BVR is a monomeric protein and consists of two structural domains: 
an N-terminal dinucleotide-binding domain (Rossmann-fold) and a C-
terminal domain, which possesses a six-stranded beta-sheet that is flanked on 
one face by alpha helices. Both domains take part in the formation of the 
active site cleft at their interface [131].  The two forms of BVR have a 
different molecular weight and each of them have two isoforms. BVR-B has 
been reported to be predominant during fetal development, while BVR-A 
dominates in adult life. 
BVR is evolutionary conserved, soluble protein found in all 
mammalian cell types analyzed to date, albeit at different levels. Considering 
mammalian species, the average sequence identity is greater than 80%. In 
such sequences several conserved key features are found: leucine zipper 
(bzip) motif, adenine dinucleotide-binding motif, serine/threonine kinase 
domain, Src homology (SH2) binding domains (YMXM and YSLF), and 
Zn/metal-binding motif [132, 133]. These features are probably fundamental 
in the activities of BVR connected with signal transduction pathways. 
Both forms generate bilirubin (BR), but only BVR-A reduces 
biliverdin (BV) into an effective intracellular anti-inflammatory agent, 
powerful antioxidant and anti-nitrosative molecule called BR-IX- alpha 
(thereafter BR). BVR-B, instead, prefers the other BV isoforms, such as BV-
β, BV-γ and BV-δ.  In details, BV is formed when heme is oxidized by the 
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heme oxygenase (HO) isozymes HO-1 and HO-2, which is reduced by BVR-
A to the highly lipophilic BR, [134, 135].  
 
Recent data from Mains et al. suggested that BVR-A, regardless its 
reductase activity, also has a unique serine/threonine/tyrosine (Ser/Thr/Tyr) 
kinase activity directly involved in insulin signaling, indeed the tyrosine 
residues in the two consensus Src homology (SH2)-binding motifs (Tyr198 
in YMKM and Tyr228 in YLSF), together with Tyr291, are targets of IR 
[136]. In particular, IR phosphorylates BVR-A on specific Tyr residues 
(Tyr198/228/291), resulting in activation of BVR-A kinase activity. Once 
activated BVR-A is able to phosphorylate IRS1 on Ser residues critical for 
the insulin signalling activation [136]. Following insulin stimulation, BVR-A 
is required for the activation and nuclear translocation of the extracellular 
signal-regulated kinases 1/2 (ERK1/2) [137]  as well as for the correct 
activation of the protein kinase B (PKB/Akt) [138] known to regulate 
memory processes in the brain [139].  
 
The two activities are differently modulated since of specific Tyr 
promoted by IR is required for the activation of its kinase activity, whereas 
the auto-phosphorylation of specific Ser/Thr residues regulates the reductase 
activity. Interestingly, Ser/Thr auto phosphorylation is independent from Tyr 
phosphorylation. 
 
An intriguing aspect is that the oxidative stress, reported in AD, 
induce the impairment of BVR-A in the hippocampus of AD and aMCI 
subjects due to reduced Tyr phosphorylation and increased 3-NT 
modifications [140].  
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In recent studies, my group showed that the dysfunction of BVR-A is 
one of the earliest events characterizing the development of brain insulin 
resistance in AD. Indeed, in a longitudinal study conducted with a triple-
transgenic murine model of AD (3×Tg-AD), we identified three phases along 
the progression of AD pathology characterized by: (1) reduced BVR-A 
protein levels associated with the hyper-activation of IR at 3 months of age; 
(2) reduced BVR-A levels and activation along with hyper-activation of both 
IR and IRS1 at 6 months of age; and (3) reduced BVR-A levels and 
activation associated with the activation of negative feed-back pathways, e.g., 
mTOR aimed to turn-off IRS1 hyperactivity and thus leading to brain insulin 
resistance. Furthermore, in vitro experiments in neuronal cell lines 
highlighted that insulin resistance phenomenon was characterized by a 
consistent impairment of BVR-A, an observation that strengthens the role of 
this protein as a regulator of the insulin signalling cascade [141]. 
 
The involvement of BVR-A in the insulin signaling is fascinating for 
two main reasons: (i) BVR-A, as IRS1, is a direct target of IR kinase activity 
and once IR-phosphorylated is able to phosphorylate IRS1 on Ser residues 
[136, 142]; and (ii) BVR-A contains specific motifs in its sequence through 
which they possibly modulates IR kinase activity both negatively and 
positively [142].  
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Figure 7. Proposed mechanism leading to BIR in AD. BVR-A, regardless its reductase 
activity, once IR-phosphorylated is able to phosphorylates IRS1 on Ser inhibitory domains.  
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2.3 Insulin as a therapy for AD 
 
In recent years, the study of insulin and insulin signaling in neuronal 
tissues has gained momentum. Proteins involved in transmission of the 
insulin signal have been detected in many brain regions, including areas 
involved in Alzheimer’s disease (AD), such as the hippocampus and 
temporal lobes [143]. Whereas insulin signaling is impaired in post mortem 
brain tissue from AD patients [144], and because it is known that insulin 
positively influences cellular processes such as growth and survival [99], 
improving insulin action in neurons has emerged as a treatment target able to 
improve cognitive function. Therefore, restoring insulin to normal levels in 
the brain by insulin treatment, as showed in laboratory animals, may provide 
therapeutic benefits in AD subjects. 
Interest in insulin as a potential therapy for AD has also stemmed 
from a number of clinical studies that indicate that individuals with Type 2 
diabetes (T2D) have an elevated risk of mild cognitive impairment and AD 
[145, 146]. In fact, a recent meta-analysis of longitudinal clinical studies 
found that T2D significantly increased AD risk independently of obesity 
[147]. 
Unlike, insulin cannot be administered orally, since it is degraded in 
the gastrointestinal track by various enzymes. In this frame, the first clinical 
studies to address the effect of insulin on the brain in the context of cognition 
were performed with intravenous insulin infusion. Increasing brain insulin 
levels in AD patients by intravenous administration has been shown to 
acutely improve performance on hippocampus-dependent memory task [148]. 
However, high systemic doses would be needed to achieve functionally 
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effective insulin concentrations in the brain, causing strong peripheral side 
effects such as hypoglycemia and induction and/or exacerbation of peripheral 
insulin resistance [149]. Therefore, oral and intravenous route of 
administration is not viable in clinical setting. 
Moreover, infusion of peripheral insulin is not a viable long-term 
therapy for AD, due to	  high risks related to hypoglycemia. Recently, direct 
drug delivery to the CNS has been investigated using intranasal 
administration. This method of administration provides rapid delivery of 
insulin to the central nervous system along bulk flow via olfactory and 
trigeminal perivascular channels, and slower delivery via olfactory bulb 
axonal transports [150, 151]. Thus, intranasal delivery of insulin is attractive 
because it is less invasive than intravenous infusion and avoids potential side 
effects of intravenous insulin infusions, such as hypoglycemia.  
Recently, National Institute of Health (NIH) has selected intranasal 
insulin administration as one of the two therapeutic strategies receiving 
substantial funding as part of the National Alzheimer’s Plan in the US [152]. 
This plan is a part of the initiatives to find a therapeutic treatment to cure AD 
by 2025. 
Several small-­‐scale clinical trials showed that intranasal insulin (INI) 
improved memory and attention in healthy participants [153], as well as in 
patients with mild cognitive impairment and AD [154]. Preclinical studies in 
different mouse models of aging or AD confirmed the cognitive 
improvement obtained by INI [155, 156], and also showed the path by which 
insulin reaches the brain [49]. However, it is still under debate the 
mechanism(s) by which INI administration might improve learning and 
memory and whether the INI treatment stimulates or not cerebral insulin 
signalling leading to a recovery from brain insulin resistance [157].   
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2. AIMS OF THIS WORK 
Within this scenario we focused on the impairment of brain insulin 
signalling during the progression of AD neuropathology. Because the 
dysfunction of BVR-A was found to be among the earliest events 
characterizing the development of brain insulin resistance in in 3xTg-AD 
mice, we decided to elucidate the role of this protein as a regulator of the 
insulin signalling cascade during the progression of AD.  
Project 1  
Brain insulin resistance is associated with increased Aβ production in 
AD although the molecular mechanisms underlying this link are still largely 
unknown. Moreover, it has been previously reported a negative association 
between BVR-A protein levels/activation with BACE1 protein levels in an 
animal model of AD, thus suggesting a possible interaction. In this frame, we 
aimed to demonstrate that BVR-A impairment is a molecular bridge linking 
brain insulin resistance with increased Aβ production. We evaluated age-
associated changes of BVR-A, BACE1, insulin signalling cascade and APP 
processing in the parietal cortex of beagles at 1, 4, 8-10 and 11-12 years and 
experiments to confirm the hypothesized mechanism(s) have been performed 
in vitro in HEK293APPswe cells. 
 
 
 
 
 
	   45	  
Project 2 
Among the strategies to ameliorate the activation of the insulin 
signalling in the brain, intranasal insulin (INI) administration is under 
evaluation in an active large trial in the field of AD. However, it is still under 
debate the mechanism(s) by which INI administration might improve 
learning and memory and whether the INI treatment stimulates or not 
cerebral insulin signalling leading to a recovery from brain insulin resistance 
[158]. The goal of this second project was to evaluate whether the beneficial 
effects of INI treatment were associated with an improvement of brain insulin 
signalling activation mediated by the amelioration of BVR-A activation. 
Hence, we hypothesized that INI administration, by favoring the IR-mediated 
activation of BVR-A, would prevent the alterations of the insulin signalling 
in the brain.  We tested in both adult (6 months of age) and aged (12 months 
of age) 3xTg-AD mice the effects of intranasal insulin administration, which 
represents an effective strategy that allows drugs to bypass the BBB and 
directly reach the brain, thereby avoiding side effects caused by systemic 
administration. 
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3. MATERIALS AND METHODS 
 
3.1 Samples 
 
 3.1.1 Animals (PROJECT 1) 
 
Aging dogs spontaneously deposit human-type amyloid β (Aβ) 
peptide [159] and thus are a natural higher mammalian model of aging that 
rodents. The canine Aβ precursor protein (APP) is virtually identical to 
human APP (~98% homology). In parallel with progressive Aβ pathology, 
aged dogs show decline in measures of learning and memory that are 
correlated with the extent and location of Aβ. Therefore, dogs represent a 
good animal model to evaluate the processes leading to Aβ accumulation in 
AD. Parietal cortex samples form fourteen beagles ranging in age from 0.15 
to 12 years were obtained from the Lovelace Respiratory Research Institute 
(Albuquerque, NM, USA). The parietal cortex was chosen as it shows 
significant Aβ accumulation with age in beagles [160]. All animals had 
documented dates of birth, comprehensive medical histories and a veterinary 
examination ensuring that the animal was in good health. According to 
previous data showing significant age-dependent decline and changes of Aβ 
levels in the brain of these dogs, our samples were divided in 4 groups based 
on their age: 1 years (n=3), 4 years (n=3), 8-10 years (n=4) and 11-12 years 
(n=4) [160].   
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3.1.2 Human AD case 
 
Slices used for the immunofluorescence analyses were collected from 
a human AD frontal cortex brain sample (male, 72 years old) obtained from 
the University of California-Irvine-ADRC Brain Tissue Repository (UCI 
ADRC) cohorts. 
 
3.1.3 Mouse colonies (PROJECT 2) 
 
4- and 10- month-old 3×Tg-AD male mice (n=8-10 per 
group/treatment) and their wild-type (WT) male littermates (n=8-10 per 
group/treatment) were used in this study. The 3×Tg-AD mice harbour 3 
mutant human genes (APPSwe, PS1M146V, and tauP301L) and have been 
genetically engineered by LaFerla and colleagues at the Department of 
Neurobiology and Behaviour, University of California, Irvine [161-163]. 
Colonies of homozygous 3×Tg-AD and WT mice were established at the 
vivarium of Puglia and Basilicata Experimental Zooprophylactic Institute 
(Foggia, Italy). The 3×Tg-AD mice background strain is C57BL6/129SvJ 
hybrid and genotypes were confirmed by PCR on tail biopsies [161].  The 
housing conditions were controlled (temperature 22°C, light from 07:00 –
19:00, humidity 50%–60%), and fresh food and water were freely available. 
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3.2 INI Treatment  
 
 Animals received intranasal insulin (Humulin®R, Ely-Lilly, 
Inadianapolis, IN, USA) administration every other day (2UI total, 4 
µL/nostril) or vehicle (saline) during 2 months.  All the experiments were 
performed in strict compliance with the Italian National Laws (DL 116/92), 
the European Communities Council Directives (86/609/EEC). All efforts 
were made to minimize the number of animals used in the study and their 
suffering. Animals were sacrificed at the selected age and the hippocampus 
and frontal cortex were extracted, flash-frozen, and stored at −80 °C until 
total protein extraction and further analyses were performed.   
 
 
 
 
Figure 8. Schematic treatment of INI treatment in 3×Tg-AD mice. 4- and 10- month-old 
3×Tg-AD mice and Wild Type (WT) were administered with intranasal Insulin 
(Humulin®R, Ely-Lilly) and Vehicle (Veh; saline) for 2 months until 6- and 12 months age 
respectively.  
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3.3 Behavioral test 
 
We used a serial behavioral testing procedure that has been validated 
and compared with single testing procedures in our laboratory, and by other 
investigators [164-167]. 
The NOR test and the MWM test were used to explore the cognitive 
behaviours, whereas the tail suspension test (TST) and the Porsolt forced 
swim test (FST) for antidepressant/depression-like coping behaviors. The 
experimental procedures were administered to the animals in this sequence, 
starting with those considered to be least stressful. The minimum interval 
between two consecutives procedures was 2 days. All tests were performed 
between 8:00 a.m. and 3:00 p.m., in a dimly lit condition. On the day of 
testing, the mice were acclimated for about 60 min in the behavioral room 
before the procedures were initiated. The apparatus was cleaned with 70% 
alcohol and water after each run. The behaviors were recorded with infrared 
lighting-sensitive CCD cameras, stored, and analysed as MPEG files. 
Experimental subjects were weighed every day during the entire period of the 
experiment.  
 
 
3.3.1 Novel object recognition test (NOR)  
 
The object recognition task is based on the spontaneous tendency of 
rodents to explore a novel object longer than a familiar one. Each mouse was 
habituated to an empty Plexiglas arena (45 × 25 × 20 cm) for 3 consecutive 
days. On training session (T1) (day 4), mice were exposed for 5 min to two 
identical objects (A+A) placed at opposite ends of the arena. 30 min and 24 h 
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later, the animals were subjected to a 5 min testing session where they were 
exposed to one object familiar (A) and to a novel object B (after 30 min) and 
object C (after 24 h). Exploration was considered as pointing the head toward 
an object at a distance of < 2.5 cm from the object, with its neck extended 
and vibrissae moving. Turning around, chewing, and sitting on the objects 
were not considered exploratory behaviors. The time of exploration was 
recorded, and an object recognition index (ORI) were calculated, such that 
ORI = (TN - TF) / (TN + TF), where TN and TF represent times of exploring 
the familiar and novel object, respectively [166, 167]. Mice that did not 
explore both objects during training were discarded from further analysis. 
Objects used in this task were carefully selected to prevent preference or 
phobic behaviors. To avoid olfactory cues, the objects were thoroughly 
cleaned with 70% ethanol and the sawdust was stirred after each trial. 
 
 
3.3.2 Morris water maze (MWM)  
 
The test was conducted in a circular tank of 1.2 meters in diameter, 
locates in a room with several extra maze cues as previously described [166]. 
Briefly, mice were trained to swim to a 14-cm-diameter circular Plexiglas 
platform submerged 1.5 cm beneath the surface of the water and invisible to 
the mouse while swimming. The water temperature was kept at 25°C 
throughout the duration of the testing. The platform was fixed in place, 
equidistant from the center of the tank and its walls. Mice were subjected to 4 
training trials per day and were alternated among 4 random starting points for 
5 consecutive days. Mice were allowed to find and escape onto the 
submerged platform. If the mice failed to find the platform within 60 sec, 
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they were manually guided to the platform and were allowed to remain on it 
for 10 sec. After this, each mouse was placed into a holding cage under a 
warming lamp for 25 sec until the start of the next trial. Retention of the 
spatial training (the probe trial) was assessed 1.5 and 24 h after the last 
training session and consisted of a 60-sec trial without the platform. Mice 
were monitored by a camera mounted in the ceiling directly above the pool, 
and all trials were stored on videotape for subsequent analysis. The 
parameters measured during the probe trial included (1) initial latency to 
cross the platform location and (2) time spent in the target quadrant (Scuderi 
et al., Transl Psychiatry 2018). Performance was monitored using the 
EthoVision XT version 7 video tracking software system (Noldus 
Information Technology Inc., Leesburg, VA). 
 
 
3.3.3 Forced swim test (FST)  
 
The FST examines the dynamics of transition from an active 
(swimming) to a passive (immobility) mode of coping in an inescapable 
water-filled pool. Enhancement of immobility normally ensues after 
exposure, a phenomenon argued to reflect learned behavioral despair [164-
167] and prevented by antidepressant treatment. The FST was performed as 
previously described [164-167]. Briefly, mice were placed individually into 
Plexiglas cylindrical bins (20 cm diameter, 50 cm high) filled with water 
(25–27°C water temperature) to a depth of 20 cm. This depth did not allow 
the tail and hindpaws to touch the floor of the bin. The mice were allowed to 
swim for 6 min. After recording, the mice were rescued using a plastic grid 
and caged near a heat source (lamp). The behavioral tracking system was 
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calibrated so that a mouse was considered immobile when making only those 
movements necessary to keep its head above water. The total duration of 
activity was determined during the last 4 min. 
 
 
3.3.4 Tail suspension test (TST)  
 
This procedure, which is also used to assess antidepressant-like 
activity, involved suspending the mouse by the tail from a lever in a white 
box (30 x 30 x 30 cm). The test has duration of 6 min and is calculated by the 
immobility time (sec) in the last 4 min of recording. These experimental 
conditions were similar to those previously described [164-167]. 
Antidepressant treatment reduces the total time the mouse remains immobile 
[165]. 
 
 
3.4 Sample preparation for western blot  
 
Total protein extracts were prepared in RIPA buffer (pH 7.4) containing 
Tris-HCl (50mM, pH 7.4), NaCl (150mM), 1% NP-40, 0.25% sodium deoxycholate, 
EDTA (1mM), 0.1% SDS, supplemented with proteases inhibitors 
[phenylmethylsulfonyl fluoride (PMSF, 1mM), sodium fluoride (NaF, 1mM) and 
sodium orthovanadate (Na3VO4, 1mM)]. Brain tissues were homogenized by 20 
passes with a Wheaton tissue homogenizer. Both brain tissues homogenates and 
collected cells were clarified by centrifugation for 1 hr at 16,000 × g, 4°C. The 
supernatant was then extracted to determine the total protein concentration by the 
Bradford assay (Pierce, Rockford, IL). 
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3.5 Slot blot analysis  
 
To evaluate total (i) protein-bound 4-hydroxy-2-nonenals (HNE) and 
(ii) 3-nitrotyrosine (3-NT) levels, brain samples (5 µl), 12% SDS (5 µl), and 
5 µl modified Laemmli buffer containing 0.125 M Tris base, pH 6.8, 4% 
(v/v) SDS, and 20% (v/v) glycerol were incubated for 20 min at room 
temperature and then loaded onto nitrocellulose membrane as described 
below.  
Proteins (250 ng) were loaded in each well on a nitrocellulose 
membrane under vacuum using a slot blot apparatus. The membrane was 
blocked in blocking buffer (3% bovine serum albumin) in PBS 0.01% (w/v) 
sodium azide and 0.2% (v/v) Tween 20 for 1 h and incubated with an anti-
2,4-dinitrophenylhydrazone (DNP) adducts polyclonal antibody (1:100, 
EMD Millipore, Billerica, MA, USA, #MAB2223) or HNE polyclonal 
antibody (1:2000, Novus Biologicals, Abingdon, United Kingdom,  #NB100-
63093) or  an anti 3-NT polyclonal antibody (1:1000, Santa Cruz, Santa 
Cruz, CA, USA,  #sc-32757) in PBS containing 0.01% (w/v) sodium azide 
and 0.2% (v/v) Tween 20 for 90 min. The membrane was washed in PBS 
following primary antibody incubation three times at intervals of 5 min each. 
The membrane was incubated after washing with an anti-rabbit IgG alkaline 
phosphatase secondary antibody (1:5000, Sigma–Aldrich, St Louis, MO, 
USA) for 1 h. The membrane was washed three times in PBS for 5 min each 
and developed with Sigma fast tablets (5-bromo-4-chloro-3-indolyl 
phosphate/nitroblue tetrazolium substrate [BCIP/NBT substrate]). Blots were 
dried, acquired with Chemi-Doc MP (Bio-Rad, Hercules, CA, USA) and 
analyzed using Image Lab software (Bio-Rad, Hercules, CA, USA). No non-
specific binding of antibody to the membrane was observed. 
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3.6 Western blot analysis 
 
For western blots, 30 µg of proteins were resolved on Criterion TGX 
Stain-Free 4-15% 18-well gel (Bio-Rad Laboratories, #5678084) in a 
Criterion large format electrophoresis cell (Bio-Rad Laboratories, #1656001) 
in TGS Running Buffer (Bio-Rad Laboratories, #1610772). Immediately 
after electrophoresis, the gel was then placed on a Chemi/UV/Stain-Free tray 
and then placed into a ChemiDoc MP imaging System (Bio-Rad 
Laboratories, #17001402) and UV-activated based on the appropriate settings 
with Image Lab Software (Bio-Rad Laboratories) to collect total protein load 
image. Following electrophoresis and gel imaging, the proteins were 
transferred via the TransBlot Turbo semi-dry blotting apparatus (Bio-Rad 
Laboratories, #1704150) onto nitrocellulose membranes (Bio-Rad, Hercules, 
CA, USA, #162-0115) and membranes were blocked with 3% bovine serum 
albumin in 0.5% Tween-20/Tris-buffered saline (TTBS) and incubated 
overnight at 4 °C with the following primary antibodies. 
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- PROJECT 1 PRIMARY ANTIBODIES: All the primary antibodies 
used and equivalent diluition are summarized in the Table 1 
 
Antibodies Brands Dilution 
BVR-A  Sigma Aldrich 1:1000 
BACE1 Cell Signaling 1:1000 
BACE1 Santa Cruz 1:1000 
Amyloid Precursor Protein, 
C-Terminal  Sigma Aldrich 1:5000 
casein kinase I α  Santa Cruz 1:1000 
β-Amyloid (6E10) BioLegend 1:1000 
IRβ Cell Signaling 1:1000 
phospho(Tyr1158/1162/1163)-IRβ  GeneTex 1:1000 
akt Cell Signaling 1:1000 
phospho(Ser473)-akt  Cell Signaling 1:1000 
mTOR Cell Signaling 1:1000 
phospho(Ser2448)-mTOR  Santa Cruz 1:500 
GSK-3β Santa Cruz 1:500 
phospho(Ser9)-GSK-3β Santa Cruz 1:500 
phospho(Try216)-GSK-3β Santa Cruz 1:500 
phospho-Tyrosine  Cell Signaling 1:1000 
3NT Santa Cruz 1:500 
phospho-serine Abcam  1:500 
 
Table 1. List of primary antibody used for Western Blot analysis to developing project 1 
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- PROJECT 2 PRIMARY ANTIBODIES: All the primary antibodies 
used and equivalent diluition are summarized in the Table 2 
 
Antibodies Brands Dilution 
BVR-A  Sigma Aldrich 1:1000 
BVR-A  Abcam  1:5000 
IRβ Cell Signaling 1:1000 
phospho(Tyr1158/1162/1163)-IRβ  GeneTex 1:1000 
IRS1 Cell Signaling 1:1000 
phospho(Ser307)-IRS1  Cell Signaling 1:500 
phospho(Ser636)-IRS1  Santa Cruz 1:500 
akt Bio-Rad 1:1000 
phospho(Ser473)-akt  Cell Signaling 1:1000 
ERK1/2  Cell Signaling 1:1000 
phospho(Thr202/Tyr204)-ERK1/2  Cell Signaling 1:1000 
mTOR Bio-Rad 1:1000 
phospho(Ser2448)-mTOR  Santa Cruz 1:500 
phospho-Tyrosine  Cell Signaling 1:2000 
IDE  Santa Cruz 1:1000 
β-Amyloid (6E10) BioLegend 1:1000 
Tau Santa Cruz 1:1000 
phospho(Ser202, Thr205)-Tau ( AT8) Thermo Scientific 1:1000 
 
Table 2. List of primary antibody used for Western Blot analysis to developing project 2 
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After 3 washes with TTBS the membranes were incubated for 60 min 
at room temperature with anti-rabbit/mouse/goat IgG secondary antibody 
conjugated with horseradish peroxidase (1:5000; Sigma–Aldrich, St Louis, 
MO, USA). Membranes were developed with Clarity ECL substrate (Bio-
Rad Laboratories, #1705061) and then acquired with Chemi-Doc MP (Bio-
Rad, Hercules, CA, USA) and analyzed using Image Lab software (Bio-Rad, 
Hercules, CA, USA) that permits the normalization of a specific protein 
signal with the β-actin signal in the same lane or total proteins loaded. 
 
 
3.7 Immunoprecipitation  
 
The immunoprecipitation procedure was performed as previously described 
[168], with minor modifications. Briefly, 150 µg of proteins extracts were dissolved 
in 500µl of RIPA buffer (10mMTris, pH 7.6; 140mM NaCl; 0.5% NP-40) 
supplemented with protease and phosphatase inhibitors and incubated with 1µg of 
BVR-A or BACE1 primary antibody at 4 °C overnight. Immunocomplexes were 
collected using protein A/G beads (Sigma–Aldrich, St Louis, MO, USA) for 2h at 4 
°C and then washed 5 times with immunoprecipitation buffer. Immunoprecipitated 
proteins were recovered by resuspending the pellets in reducing SDS buffers and 
subjected to electrophoresis on 12% and 4%-15% gels followed by western blot 
analysis. Total BVR-A or BACE1 were used as a loading control as previously 
described [169-172]. 
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3.8 Cell culture and treatments  
 
The HEK cells were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-
glutamine, penicillin (20 units/ml) and streptomycin (20 mg/ml), (GIBCO, 
Gaithersburg, MD, U.S.A.). Cells were maintained at 37°C in a saturated 
humidity atmosphere containing 95% air and 5% CO2. Cells were seeded at 
density of 40x103/cm2 in 6 wells culture dishes for the subsequent treatments 
aimed to (i) induce the activation the insulin signalling cascade, (ii) induce 
insulin resistance and (iii) recovery cells from insulin resistance. In a first set 
of experiments HEK cells were treated with insulin (humulin®R, Ely-Lilly, 
Inadianapolis, IN, USA) 100 nM for different times (2-6-12-24 h) to select 
the best time-to-treatment to be used in the other experiments. Then, to 
mimic insulin over-exposure known to promote insulin resistance [173], at 
the selected time, cells were treated with an additional dose of insulin (100 
nM) for other 2 h. Thereafter, medium was discarded, cells were washed 
twice with PBS, and rechallenged with DMEM with 10% FBS containing 
insulin (100 nM-500 nM-1 uM) for additional two hours to mimic the effect 
of INI treatment aimed to recover insulin signalling cascade activation. In 
parallel, to test the effects produced by the silencing of BVR-A on insulin 
signalling activation, HEK cells were seeded at density of 40x103/cm2 in 6 
wells culture dishes. After 24 h medium has been replaced with DMEM with 
10% FBS, without antibiotics.  Following, cells have been transfected with 
10 pmol of a small-interfering RNA (siRNA) for BVR-A (Ambion, Life 
Technologies, LuBioScience GmbH, Lucerne, Switzerland, #4392420) using 
Lipofectamine® RNAiMAX reagent (Invitrogen, Life Technologies, 
LuBioScience GmbH, Lucerne, Switzerland, #13778-030) according to the 
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manufacturer’s protocol, and then treated with insulin as described above. At 
the end of each treatment, cells were washed twice with PBS, collected and 
proteins were extracted as described below.  In parallel, collected medium 
(mixed with protease and phosphatase inhibitors) was treated with 
trichloroacetic acid to precipitate soluble proteins pools to be used for the 
analysis of extracellular Aβ levels. 
 
 
3.9 Peptide treatments 
 
HEK cells were plated as described above and then treated with the 
myristoilated peptide (myr-KYCCSRK) (Biomatik, Wilmington, Delaware, 
USA) at the dose of 10 and 20 µM [174, 175] in combination with insulin 
(100 or 500 nM) for 2 h.   
 
 
3.10 Whole-cell LTP in organotypic hippocampal slices 
 
Hippocampal organotypic slice cultures were prepared from postnatal 
day 4–7 rats through a McIllwain tissue chopper as previously described in 
Spinelli et al. 2017. Slices (350  µm) were placed on semiporous membranes 
(Millipore) fed by tissue medium (for 1 liter: 788 ml 1xMEM (GIBCO, 
#11575-032, 7.16 g HEPES, 0.49 g NaHCO3, 4.8 g D-glucose, 50 µl 25% 
ascorbic acid, 50 µl (10 mg/ml) insulin, 200 ml horse serum, 2 ml 1 M 
MgSO4, 1 ml 1 M CaCl2). Slices were incubated at 35 °C in 5% CO2 and 
after 5–7 days CA1 pyramidal neurons were transfected with ballistic gene 
transfer (Gene-Gun, Bio-Rad, CA, USA). shRNAs were transfected together 
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with a plasmid enconding enhanced green fluorescent protein (EGFP) to 
identify the transfected neurons. LTP experiments were performed 2 days 
after transfection after stimulating the Schaffer collateral fibers by means of a 
bipolar tungsten electrode (FHC, Neural microTargeting Worldwide) as 
previously described [176, 177]. Slices were incubated in artificial 
cerebrospinal fluid (ACSF) containing (in mM): 119 NaCl, 2.5 KCl, 4 CaCl2, 
4 MgCl2, 1 NaH2PO4, 26 NaHCO3, 11 D-glucose, and 0.005 2-
chloroadenosine, gassed with 95% O2/5% CO2. Whole-cell recording pipettes 
(3–4 MΩ) were filled with a solution containing (in mM): 135 CsMeSO3, 8 
NaCl, 10 HEPES, 0.25 EGTA, 2 Mg2ATP, 0.3 Na3GTP, 0.1 spermine, 7 
phosphocreatine, and 5 QX-314, pH 7.25–7.30 (osmolarity 300). Data were 
collected with a MultiClamp 700B amplifier (Molecular Devices), digitized 
at 10 kHz using the Digidata 1440A data acquisition system (Molecular 
Devices) and analysed using Clampfit software (Molecular Devices). LTP 
was induced by pairing 200 stimuli at 2 Hz with a holding potential of 0 mV. 
To avoid “wash-out” of LTP, the induction protocol was applied within 5–7 
min of achieving whole-cell configuration, The magnitude of LTP was 
calculated on basis of the averaged EPSC values during the last 5 min of 
recordings (from min 25 to min 30). LTP magnitude was expressed as the 
percentage change in the mean EPSC peak amplitude normalized to baseline 
values 100% (i.e., mean values of recording before LTP induction). 
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3.11  Immunohistochemistry 
 
Free-floating 50 µm-thick sections were used for 
immunohistochemical studies. Briefly, for single labeling, all sections were 
washed with 0.1 M Tris-buffered saline (TBS), pH 7.4, and then pretreated 
with 3% hydrogen peroxide in 10% methanol to block endogenous 
peroxidase activity. Sections were subsequently washed in TBS with 0.1% 
Triton X-100 and then blocked for thirty minutes in TBS-A with 3% bovine 
serum albumin (TBS-B). Sections were further incubated overnight at room 
temperature with the primary antibody: BVR-A (anti-rabbit, 1:2000) and 
BACE1 (anti-rabbit, 1:500) for PROJECT 1. Following two washes with 
TBS-A and a wash in TBS-B, sections were incubated in anti-rabbit 
biotinylated anti-IgG (1 hour) and then in avidin biotin complex (1 hour) 
(ABC, Elite Immunoperoxidase, Vector Laboratories, Burlingame, CA, 
USA). The primary antibody was visualized using brown DAB substrate 
(Vector Laboratories). For double labeling experiments where both 
antibodies were raised in the same species intervening formaldehyde 
treatment was used between the first and second immunolabel. Primary 
antibody labeling was detected using the brown DAB substrate (Vector 
Labs), while the second label was visualized using the Blue SG substrate 
(Vector Labs). 
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3.12  Confocal microscopy  
 
Brain sections were incubated overnight at room temperature with the 
same primary antibody used for the immunohistochemistry. Alexa Fluor 
secondary antibody 488 (1:200, Molecular Probes, Eugene, OR) was used to 
visualize the first label and Alexa Fluor secondary antibody 568 (1:200, 
Molecular Probes, Eugene, OR) was used to visualize the second label. 
Sections were allowed to dry on slides prior to coverslipping with 
VectaShield mounting media with DAPI (Vector Laboratories, Burlingame, 
CA, USA). Confocal images were taken with a Nikon confocal microscope 
system A1+ and NIS-Elements C's software (Carl Zeiss, Inc., Thornwood, 
NY). Single plane images were acquired with a 40x Plan Fluor immersion 
objective (NA 1.3) with emission long pass of 505 nm for the detection of 
BACE1 antibody (green channel, Alexa Fluor 488) and 550-600 nm for the 
detection of BVR-A (red channel, Alexa Fluor 568).  
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3.13  Statistical analyses 
 
All data are presented as means ± SEM of n independent samples per 
group. Behavioral and biochemical data were analysed by two-way analyses 
of variance (ANOVA) with genotype (3×Tg-AD vs WT) and treatment 
(Insulin vs vehicle) as between-subject factors. Tukey’s honestly significant 
difference (HSD) test or Bonferroni’s test were used for multiple post-hoc 
comparisons when required. Student t-test was used to evaluate differences 
observed in aging dogs study and cellular experiments. p<0.05 was 
considered significantly different from the reference value. All statistical 
analysis was performed using GraphPad Prism 5.0 software. 
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PROJECT 1  
 
4. RESULTS 
 
4.1 Early Impairment of insulin signalling cascade in the 
parietal cortex of beagles   
 
We first characterized the activation state of the insulin signalling 
cascade by evaluating age-associated changes of IR, Akt, GSK-3β and 
mTOR protein levels and phosphorylation in the parietal cortex (Fig. 9A). 
We were not able to evaluate changes of IRS1 because none of the antibodies 
we tested to evaluate protein levels or Ser307/Ser636 phosphorylation of 
IRS1 recognized canine IRS1. We found that IR protein levels were 
significantly increased at 4 years (+ 70%, p= 0.02) with respect to 1 year-old 
dogs and become reduced in older dogs both at 8-10 years (-20%, p=0.02) 
and 11-12 years (-35% , p= 0.04), with respect to 4 years-old dogs. When we 
evaluated the active form of IR with respect to total protein levels (activation 
index) in each group, we found that the pIRTyr1158/1162/1163/IR ratio was 
significantly reduced at 4 years (-80%, p=0.05), at 8 years (-60%, p=0.05) 
and at 11-12 years (-70%, p=0.03) with respect to younger dogs (Fig. 9B). 
These data therefore suggest that an early impairment of the IR activation 
characterizes the parietal cortex of these dogs along the course of their life.  
In agreement with reduced IR activation, we also observed a significant 
reduction of the Akt activation index (pAktSer473/Akt ratio) starting at 4 years 
(-20%, p=0.03) and still evident at 12 years (–20%, p=0.02) (Fig. 9C). Two 
of the main targets of Akt activity are GSK-3β and the mTOR. GSK-3β is a 
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constitutively activated protein inhibited following Akt activation, while 
mTOR is activated by Akt [178, 179]. No changes of mTOR protein levels 
were observed, while we found a significant decrease of mTOR activation 
index (pmTORSer2448/mTOR: 8-10 year, –25%, p=0.04; 11-12 years, –40%, 
p=0.04) (Fig. 9D). While reduced mTOR activation parallels reduced Akt 
activation, similar changes did not characterize GSK-3β. Although we found 
no changes of GSK-3β protein levels, GSK-3β  activatory (Tyr216) and 
inhibitory (Ser9) phosphorylation revealed that the GSK-3β activation index 
(pTyr216GSK-3β/GSK-3β) was significantly reduced only in aged beagles at 
11-12 years (-40%, p=0.01), while the inactivation index (pSer9GSK-3β/GSK-
3β) was significantly increased quite early, starting at 4 years of age (+50%, 
p=0.02) (Fig. 9E). Interestingly, the GSK-3β inactivation/activation indexes 
ratio resulted in a significant increased GSK-3β inactivation (4 years, +80%, 
p=0.01; 8-10 years, +70, p=0.05; and 11-12 years, +140%, p=0.02), thus 
indicating that GSK-3β is mainly inactivated in the parietal cortex with age 
(Fig. 9F). 
These results suggest that beagles develop alterations of insulin 
signaling in the parietal cortex, underlying a condition of brain insulin 
resistance similar to those observed in AD [180-183].  
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Figure 9. Early impairment of insulin signalling in the parietal cortex of beagles. 
Proteins associated with insulin signalling including IR protein levels, IR activation 
[pIR(Tyr1162/1163)], AKT protein levels, AKT activation [pAKT(Ser473)], mTOR protein levels, 
mTOR activation [mTOR(Ser2558)], GSK3β protein levels, GSK-3β inactivation [GSK-3β(Ser9)] 
and activation [GSK-3β(Tyr216)] were measured by Western Blot in the parietal cortex of 
beagles at 0-1 (n=3), 4 (n=3), 8-10 (n=4) and 11-12 (n=4) years. Panel A: western blot 
analyses. Representative bands are shown. Panels B-C-D-E-F: densitometric analyses of 
western blot protein bands. Protein levels were normalized per total protein load. IR, AKT, 
mTOR and GSK-3β-associated phosphorylation were normalized by taking into account the 
respective protein levels and are expressed as the ratio between the phosphorylated form and 
the total protein levels: pIR(Tyr1162/1163)/IR, pAKT(Ser473)/AKT, pGSK-3β(Ser9)/GSK-3β and 
pGSK-3β(Tyr216)/GSK-3β  and pmTOR(SER2448)/mTOR. Densitometric values shown are given 
as percentage of 1 year set as 100%. Mean ± SEM, *p < 0.05 vs 0-1years and #p < 0.05 vs 4 
years (Student's t-test). 
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4.2 Reduced BVR-A activation in the parietal cortex of 
aged beagles 
 
We previously reported reduced BVR-A phosphorylation along with 
an increase of 3-nitrotyrosine (3-NT) on BVR-A, which negatively affected 
BVR kinase activity in post-mortem hippocampus from AD and amnestic 
mild cognitive impairment (MCI) subjects [171, 172, 184]. Furthermore, in a 
longitudinal study conducted in 3xTg-AD mice we demonstrated that 
reduced BVR-A Tyr phosphorylation (observed at 6 months) precedes the 
increase of 3-NT modifications (observed at 12 months) on BVR-A in the 
hippocampus [141]. Together these alterations may contribute to a persistent 
impairment of BVR-A kinase activity, which triggers the alterations of brain 
insulin signaling in parallel with the progression of AD pathology [141]. 
Based on this premise, we evaluated changes of BVR-A protein 
levels, activatory phosphorylation (pBVR-ATyr) and oxidative stress-induced 
post-translational modifications (3NT-BVR-A) in the parietal cortex of 
beagles with age (Fig. 10A&C). No significant changes for BVR-A protein 
levels were observed (Fig. 10B). With regard to the BVR-A activation index 
(pBVR-ATyr/BVR-A), we found a significant decrease at 4 years (-35%, 
p=0.01), at 8-10 years (-40%, p=0.001) and at 11-12 years (-20%, p=0.01) 
(Fig. 10D). 3-NT levels on BVR-A were significantly increased only in the 
oldest dogs (+40%, p=0.04) (Fig.10E). Keeping in mind that phosphorylation 
and nitration processes share the same targets – i.e., Tyr residues –  and are 
mutually exclusive events [185] the evaluation of 3-NT/pTyr levels on BVR-
A show a significant increase of this ratio starting at 4 years and persisting 
until 11-12 years (4 years, +60%, p=0.03; 8-10 years, +60, p=0.009; and 11-
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12 years, +70%, p=0.04) (Fig. 10F).  This observation may suggest that 
reduced BVR-A phosphorylation could leave BVR-A Tyr residues available 
for oxidative stress-induced modifications. Indeed, total 3-NT modifications 
start to accumulate at 4 years becoming significant at 8-10 years (+40%, 
p=0.01) and remaining elevated also at 11-12 years  in the parietal cortex 
(Fig. 10G). 
Overall these results further demonstrate that the impairment of BVR-
A – primarily driven by reduced Tyr phosphorylation –  is an early event 
during the aging process and is associated with a dysfunction of the insulin 
signaling cascade in the brain. 
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Figure 10. BVR-A activation in the parietal cortex of beagles. BVR-A protein 
levels, Tyr phosphorylation (pTyr) and 3-nitrotyrosine (3-NT) modifications on 
BVR-A were measured by immunoprecipitation/Western Blot in the parietal cortex 
of beagles at 0-1 (n=3), 4 (n=3), 8-10 (n=4) and 11-12 (n=4) years. Panels A-C: 
western blot analyses. Representative bands are shown. Panels B-D-E-F-G: 
densitometric analyses of western blot protein bands. BVR-A protein levels were 
normalized per total protein load. pTyr levels and 3-NTmodifications on BVR-A 
were normalized by using total BVR-A as loading control. Densitometric values 
shown are given as percentage of 1 year set as 100%. Mean ± SEM, *p < 0.05 vs 0-1 
years and ºp < 0.05 vs 8-10 years (Student's t-test). 
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4.3 Reduced BVR-A activation is associated with an increased 
CKI-mediated phosphorylation of BACE1 in the parietal 
cortex 
 
The negative association between BVR-A activation and BACE1 
levels found in our previous work [186] likely indicated the possibility of an 
interaction between these two proteins.  BVR-A possess a Ser/Thr/Tyr kinase 
activity [187] and previous studies reported that Ser phosphorylation of 
BACE1 regulates BACE1 trafficking from the endosomes to the plasma 
membrane [188, 189]. For that reason, we first hypothesized that BVR-A 
could phosphorylate BACE1 as BVR-A does with other proteins [187, 190]. 
That said, we tested the hypothesis that BVR-A and BACE1 can form a 
complex. We first evaluated total BACE1 protein levels, that were 
significantly decreased at 8-10 years (-20%, p=0.01) with respect to younger 
dogs, and also reduced at 11-12 years (Fig. 11B). Then, we looked at the 
possible interaction between BVR-A and BACE1 through the 
immunoprecipitation of BACE1 followed by the evaluation of the levels of 
total BVR-A as well as its active form (pBVR-ATyr) bound to BACE1 (Fig. 
11C). Our data demonstrated that BVR-A immunoprecipitates with BACE1 
and that a significant decrease of their interaction occurs only in aged dogs at 
11-12 years (-20%, p=0.01) with respect to younger dogs (Fig. 11D).  
Interestingly, the evaluation of the pBVR-ATyr /BACE1 complex showed a 
significant reduction of the active form of BVR-A bound to BACE1 both at 
8-10 years (-30%, p=0.03) and 11-12 years (- 40%, p=0.05) compared to 
younger dogs (Fig. 11E).  
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Figure 11. Reduced BVR-A activation is associated with increased Ser phosphorylation 
of BACE1 in the parietal cortex of beagles. BACE1 protein levels, BVR-A levels, pBVR-
ATyr levels and BACE1 Ser phosphorylation levels were measured by immunoprecipitation/ 
Western Blot in the parietal cortex of beagles at 0-1 (n=3), 4 (n=3), 8-10 (n=4) and 11-12 
(n=4) years. Panels A-C-G: western blot analyses. Representative bands are shown. Panels 
B-D-E-F-H: densitometric analyses of western blot protein bands. BACE1 protein levels 
were normalized per total protein load. BVR-A levels and BACE1 Ser phosphorylation 
levels on BACE1 were normalized by using total BACE1 as loading control. pBVR-ATyr 
levels on BACE1 has been calculated by normalizing first pBVR-ATyr for total BVR-A and 
then by normalizing the obtained value for total BACE1 used as loading control. BACE1 
levels on BVR-A were normalized using total BVR-A as loading control. Densitometric 
values shown are given as percentage of 1 year set as 100%. Mean ± SEM, *p < 0.05 vs 0-1 
years, #p < 0.05 vs 4 years and ºp < 0.05 vs 8-10 years (Student's t-test) 
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These data agree with the observed impairment of BVR-A in the 
parietal cortex, which is also reflected on the interaction with BACE1. To 
further prove that BVR-A effectively interacts with BACE1, we 
immunoprecipitated BVR-A and then we looked for BACE1. As showed in 
Fig. 3H, we found that BACE1 immunopreciptated together with BVR-A, 
although no significant changes occur with age. We also evaluated the 
expression of these proteins in the brain by immunohistochemistry and 
immunofluorescence analyses that confirmed the neuronal co-localization of 
BVR-A and BACE1 in the brain of beagles at (8-10 years) (Fig. 12). 
Furthermore, co-localization was also observed in a human AD case (Fig. 
12).  
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Figure 12. BVR-A and BACE1 co-localization in neurons. Double-staining 
immunohistochemistry with anti-BACE1 antibody (brown) and anti-BVR-A antibody (blue) 
in the parietal cortex of beagles at 8-10 years. Some neurons show positive co-localization 
(arrows) and show positive signal for BACE1 (arrowhead) (Panel A&B). Representative 
confocal immunofluorescence double labeling in the parietal cortex of beagles at 8-10 years 
utilizing BACE1 (green, Panel C) and BVR-A (red, Panel D) revealed co-localization of the 
two antibodies within neurons (Panel E). Representative confocal immunofluorescence 
double labeling in the frontal cortex of a human AD brain (Panel F-G-H). 
 
 
 
 
 
 
 
 
 
 
	   74	  
To test our hypothesis about a possible BVR-A-mediated 
phosphorylation of BACE1, we looked at BACE1 Ser phosphorylation 
levels. Our results reveal that BACE1 is significantly phosphorylated on Ser 
residues at 8-10 years (+70%, p=0.05) with respect to 1 year (Fig. 11F). This 
finding, however, was not consistent with our hypothesis because increased 
BACE1 Ser phosphorylation was associated with reduced pBVR-ATyr. For 
that reason, we suggest the existence of a third player, which mediates the 
phosphorylation of BACE1 and that could be normally inhibited by BVR-A. 
Among the proteins known to phosphorylate BACE1, CKI was previously 
reported to have a role in AD [191-194], since it can phosphorylate mature 
BACE1 at the serine residue 498 in the C-terminal domain to regulate 
BACE1 recycling from the endosomes to the plasma membrane [188, 189].  
We therefore evaluated the age-associated changes of CKIα protein total 
levels and its association with BACE1 in the parietal cortex (Fig. 13A). We 
found that CKIα protein levels were significantly increased in all the aged 
groups relative to 1 year old animals (4 years, +50%, p=0.007; 8-10 years, 
+60%, p=0.01; and 11-12 years, +60%, p=0.01) (Fig. 13B). Furthermore, a 
significant increase of CKIα bound to BACE1 (CKIα/BACE1) at 8-10 years 
(+30%, p=0.03) was observed, compared to the younger group of animals 
(Fig. 13D).  
These results are in agreement both with increased BACE1 Ser 
phosphorylation and reduced BVR-A activation observed at 8-10 years, thus 
supporting our hypothesis that under normal conditions, BVR-A could 
prevent the CKI-mediated phosphorylation of BACE1, while the disruption 
of BVR-A kinase activity allows such phosphorylation. 
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Figure 13. Increased CKIα levels and CKIα association with BACE1 in parietal cortex 
of beagles. CKIα protein levels and CKIα levels with BACE1 were measured by 
immunoprecipitation/ Western Blot in the parietal cortex of beagles at 0-1 (n=3), 4 (n=3), 8-
10 (n=4) and 11-12 (n=4) years. Panels A-C: western blot analyses. Representative bands are 
shown. Panels B-D: densitometric analyses of western blot protein bands. CKIα protein 
levels were normalized per total protein load. CKIα with BACE1 levels were normalized by 
using total BACE1 as loading control. BACE1 levels on BVR-A were normalized using total 
BVR-A as loading control. Densitometric values shown are given as percentage of 1 year set 
as 100%. Mean ± SEM, *p < 0.05 vs 0-1 years, **p < 0.01 vs 0-1 years, #p < 0.05 vs 4 years 
and ºp < 0.05 vs 8-10 years (Student's t-test). 
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4.4  Increased BACE1 Ser phosphorylation is associated 
with increased Aβ levels in the parietal cortex  
 
Phosphorylation favours the recycling of BACE1 from the early 
endosome to the trans-Golgi network (TGN) and subsequent re-delivery to 
the plasma membrane [195]. Furthermore, phosphorylated BACE1 
colocalized with its protein substrate βAPP and the over-expression of 
constitutive phosphorylated BACE1 protein is associated with increased Aβ 
production in vitro [188]. To test whether increased BACE1 Ser 
phosphorylation was associated with an increase of Aβ levels, we evaluated 
age-associated changes of APP and its cleavage products (Fig. 14A). 
 Our data demonstrate a decrease of APP protein levels with age, 
which becomes significant at 11-12 years (-20%, p=0.003) (Fig. 14B). In 
parallel, we found an age-dependent increase of the BACE1-dependent APP 
cleavage product  (APP CTFβ) without changes of the α-secretase mediated 
APP cleavage products (APP CTFα). Increased CTFβ levels becomes 
significant at 8-10 years (+ 100%, p=0.02) with respect to 1 year old dogs 
(Fig. 14D&E). Furthermore, the evaluation of the CTFβ / CTFα ratio show a 
significant increase at the same age (+130%, p= 0.02) (Fig. 14F). Along with 
these changes, we found a significant increase of Aβ dodecamer (Aβ*56, + 
300%, p=0.04) at 8-10 years (Fig. 14C), that, together with the observed 
increase of APP CTFβ at the same age, suggest an increase of the 
amyloidogenic pathway.  
These observations therefore suggest that increased CKI-mediated 
BACE1 Ser phosphorylation favors the amyloidogenic cleavage of APP, 
resulting in increased Aβ levels in the brain. 
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Figure 14. Aβ oligomers and APP production in parietal cortex of beagles. APP, sAPPα, 
sAPPβ and Aβ protein levels were measured by Western Blot in the parietal cortex of 
beagles at 0-1 (n=3), 4 (n=3), 8-10 (n=4) and 11-12 (n=4) years. Panel A: western blot 
analyses. Representative bands are shown. Panels B-C-D-E-F: densitometric analyses of 
western blot protein bands. APP, sAPPα, sAPPβ and Aβ levels were normalized per total 
protein load. Densitometric values shown are given as percentage of 1 year set as 100%. 
Mean ± SEM, *p < 0.05 vs 0-1 years and  #p < 0.05 vs 4 years (Student's t-test).  
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4.5 Insulin resistance-associated BVR-A impairment 
promotes the increase of Aβ production by favoring the CKI-
mediated Ser phosphorylation of BACE1 
 
In order to demonstrate that decreased BVR-A activation favors CKI-
mediated phosphorylation of BACE1 under insulin resistance conditions, we 
took advantage of a previously published protocol designed to induce insulin 
resistance in vitro. Indeed, we reported that loss of BVR-A obtained through 
a specific siRNA triggers the development of insulin resistance when cells 
are treated with a physiological dose of insulin [141]. 
We found that insulin treatment (100 nM, for 2h) led to a significant 
increase of BVR-A (+20%, p=0.01) and BACE1 (+80%, p=0.01) protein 
levels, without alterations of CKIα levels, in control cells (Fig. 15B,C&D, 
column 2). These changes were not associated with increased Aβ production 
(Fig. 15H, column 2). Indeed, a consistent reduction of Aβ*56 release in the 
medium (-40%, p=0.01) was observed. Insulin treatment led to an increased 
association of CKIα to BACE1 (+200%, p=0.01) (Fig. 15M, column 2). 
However, CKIα does not affect BACE1 Ser phosphorylation, which was 
found to be significantly reduced (-80%, p=0.03) (Fig. 15L, column 2). 
Overall, it seems that despite an increased association between CKIα and 
BACE1 following insulin treatment, CKIα is unable to mediate the 
phosphorylation of BACE1, thus resulting in a lower Aβ*56 production. 
To demonstrate that BVR-A has a role in this mechanism, we silenced 
BVR-A and we looked at the effect of insulin. Insulin led to a significant 
increase of CKIα protein levels (+20%, p=0.01) in siRNA-treated cells, 
without significant changes of BACE1 (Fig. 15C&D, column 5).  Further, we 
observed a significant increase of extracellular Aβ*56 content (+30, 
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p=0.0004) in siRNA-treated cells exposed to insulin, with respect to siRNA-
treated cells (Fig. 15H, column 4 vs column 5).  In agreement with our 
hypothesis, we found that silencing BVR-A did not promote changes of 
CKIα-bound to BACE1 (Fig. 15M, column 4), but led to a significant 
increase in phosphorylation of BACE1 (+250%, p=0.01) (Fig. 15L, column 4 
vs column 5). Insulin treatment in siRNA-treated cells increased the 
association of CKIα with BACE1 (+300%, p=0.01) (Fig. 15M, column 4 vs 
column 5) and further increased the phosphorylation of BACE1 (+150%, 
p=0.01) with respect to siRNA-treated cells not exposed to insulin (Fig. 15L, 
column 4 vs column 5).  When we compared the effect of insulin in siRNA-
treated cells to control cells, we found that insulin promotes a significant 
increase of both intracellular (+50, p=0.05) and extracellular Aβ levels 
(+70%, p=0.03) (Fig. 15G&H, column 2 vs column 5) along with an increase 
of BACE1 phosphorylation (+400%, p=0.01) (Fig. 15L, column 3 vs column 
5), despite no changes in the association between CKI and BACE1 (Fig. 
15M, column 2 vs column 5). 
Overall, these results are consistent with the notion that BVR-A plays 
a role in controlling the trafficking of BACE1 and that loss of BVR-A 
function is associated with an increased recycling of BACE1, leading to 
increased Aβ production.   
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Figure 15. Insulin resistance-associated BVR-A impairment promotes the increase of 
Aβ production by favoring the CKIα-mediated Ser phosphorylation of BACE1. Western 
blot analysis of BVR-A, BACE1, CKIα, APP, Aβ intracellular, Aβ extracellular, APP CTFs 
protein levels in HEK293APPsw cells treated with BVR-A siRNA and insulin (100nM). 
Panel A: Western blot analyses. Representative bands are shown. Panels B-C-D-E-F-G-H: 
densitometric analyses of western blot protein bands. BVR-A, BACE1, CKIα, APP, Aβ 
intracellular, Aβ extracellular, APP CTFs protein levels were normalized per total protein 
load. Densitometric values shown are given as percentage of Ctr cells set as 100% (n=3 
independent cultures/group). Mean ± SEM, *p < 0.05 and **p < 0.01 vs Ctr cells; ##p < 0.01 
and ###p < 0.001 siRNA-treated cells; ºp < 0.05, ººp < 0.01 and ºººp < 0.001 vs insulin-treated 
cells (Student's t-test). Panel I: BACE1 Ser phosphorylation levels and CKIα levels on 
BACE1 were measured by immunoprecipitation/ Western Blot in HEK293APPsw cells 
treated with BVR-A siRNA and insulin (100 nM). Western blot analyses. Representative 
bands are shown. Panels L-M: Densitometric analyses of western blot protein bands. BACE1 
Ser phosphorylation levels and CKIα levels on BACE1 were normalized by using total 
BACE1 as loading control. Densitometric values shown are given as percentage of Ctr set as 
100% (n=3 independent cultures/group). Mean ± SEM, **p < 0.01 vs Ctr cells, ##p < 0.01 vs 
siRNA-treated cells (Student's t-test) 
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5. DISCUSSION 
 
Several studies highlight that brain insulin resistance is directly 
associated with increased Aβ production [207, 208] or reduced Aβ clearance 
[209-211] in AD. Furthermore, brain insulin resistance may also exacerbate 
pre-existing AD pathology [181, 212]. While the role of Aβ in promoting 
brain insulin resistance – mainly by reducing the membrane-bound fraction 
of IR available for binding with insulin [213-217] – is known, the molecular 
mechanisms through which brain insulin resistance favors the production of 
β-amyloid peptides are still largely unknown.  
In this context, we describe a potential mechanism through which the 
impairment of BVR-A (known to trigger the development of brain insulin 
resistance [141]) promotes BACE1-mediated cleavage of APP and increases 
Aβ levels in the brain (Fig. 18). In the hypothesized pathway, an interaction 
among BVR-A/BACE1/CKIα occurs. BACE1 immunoprecipitates with both 
BVR-A and CKIα. Our data also suggest that BVR-A exerts a regulatory role 
on CKIα, thus preventing CKIα-mediated Ser phosphorylation of BACE1 
and consequent recycling of BACE1 to plasma membranes [195].  The early 
impairment of BVR-A kinase activity would trigger BACE1 recycling at the 
plasma membrane along with alterations of insulin signalling during the 
progression of AD pathology in the parietal cortex, thus representing a 
molecular link between brain insulin resistance and Aβ production.  
The ability of BVR-A to interact with other proteins has precedents in 
the literature. Indeed, several sequence motifs within the BVR-A structure 
were identified as possible protein–protein interaction sites: the cysteine-
containing 275KKRILHC and 290KYCCSRK in the C-terminal α-helix, and 
the two SH2-binding motifs (198YMKM and 228YLSF) [175].  BVR-A 
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influences cellular signaling pathways by different mechanisms (reviewed in 
[187]) among which: (i) kinase-kinase activity for the transfer of phosphate 
groups to the kinase substrate (i.e., BVR-A/IRS1 and BVR-A/IPKC-ζ ); (ii) 
binding to and inducing change in the conformation of the kinase substrate 
(i.e., BVR-A/Akt and BVR-A/PKC-βII); (iii) translocating signaling effector 
molecules through the nuclear pore complexes (i.e., BVR-A/ERK1/2); and 
(iv) being a scaffold protein for the formation of tertiary signaling modules 
involving its C- and D-boxes in the cytoplasm and in the nucleus  (i.e., BVR-
A/MEK/ERK and BVR-A/PKCσ/ERK2).  
  Our data demonstrate that BVR-A physically interacts with BACE1, 
since they have been co-immunoprecipitated from parietal cortex samples. 
Furthermore, they have been found to co-localize in neurons both in dogs and 
AD. However, the simple binding of BVR-A seems to not affect BACE1 Ser 
phosphorylation. Rather, since the levels of pTyr-BVR-A (active) bound to 
BACE1 are significantly reduced at 8 years of age when increased BACE1 
Ser phosphorylation and increased Aβ levels are observed, we think that 
BVR-A influences BACE1 mainly through a kinase-kinase mechanism 
involving CKIα. CK1 proteins are characterized by multiple serine sites 
whose phosphorylation inhibits their activity [218]. Therefore BVR-A Ser 
kinase activity could be implicated in this process. Indeed, the association 
between BACE1 and CKIα occurs independently from the presence of BVR-
A, thus excluding the possibility that BVR-A normally limits the interaction 
between BACE1 and CKIα. Conversely, either the reduced BVR-A 
activation or the silencing of BVR-A are associated with increased BACE1 
Ser phosphorylation in parietal cortex and HEK293APPsw cells, 
respectively. The BVR-A-mediated inhibition of CKIα is further strengthen 
by our data showing that insulin treatment (known to induce BVR-A 
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activation [141, 199]) is associated with reduced BACE1 Ser 
phosphorylation levels in HEK293APPsw cells, while the opposite occurs in 
cells lacking BVR-A. Considering that BACE1 Ser phosphorylation has been 
demonstrated to be specifically mediated by CKIα [188, 189], the suggested 
inhibitory role for BVR-A on CKIα could represent a conceivable 
mechanism.  
These results, in agreement with the proposed role for the CKI protein 
family in human AD [191-194, 219], further strengthen the validity of 
beagles as a spontaneous mammalian model to study Aβ-associated 
pathology in aging and AD. In particular, CKIα, CKIδ and CKIε were 
elevated in human AD hippocampus [219]. Furthermore, CKI isoforms 
accumulate in AD lesions but the pattern varies with isoform. CKIα strongly 
co-localizes with NFTs, whereas Ck1δ immunostaining is far more intense in 
granulovacuolar degeneration than in NFTs [220]. Considering that the 
studies that demonstrated CKI-mediated phosphorylation of BACE1 did not 
discriminate among the different CKI isoforms [188, 189, 195], we selected 
CKIα as our target because among the antibodies tested only those against 
this isoform recognized the canine protein.  Although the different isoforms 
differ in length or in the C-terminal (24–200 amino acids) non-catalytic 
domain, they show a high homology in their catalytic domain [218]. 
The impairment of BVR-A kinase activity not only favours CKIα-
mediated phosphorylation of BACE1 but is also associated with molecular 
alterations of the insulin signalling cascade in the parietal cortex. This is of 
interest in light of the fact that insulin signalling (i) regulates synaptic 
plasticity in the brain thus affecting cognitive functions [196, 200, 221-224] 
and (ii) is disrupted in AD (reviewed in [180, 225]).  
Mechanistically, insulin resistance phenomenon is characterized by an 
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inadequate response to insulin by target cells [226] due to reduced IR 
levels/activation and/or increased levels of inhibitory phosphorylation of 
IRS1 [181, 207, 227].  
Due to the similarities in the molecular processes underlying the 
development insulin resistance in type 2 diabetes (T2DM), AD has been also 
defined as type 3 diabetes [228-230]. In this context, T2DM has been 
proposed as a risk factor for AD principally because the high levels of 
circulating insulin observed in the first phase of T2DM, may elevate brain 
and cerebrospinal fluid insulin levels, which in turn down-regulates IR at the 
blood brain barrier and reduces insulin transport and insulin signalling 
activation into the brain [231-234].  
However, brain insulin resistance can also develop independently 
from systemic insulin resistance. Most of studies conducted so far – in 
particular those coming from De Felice group – clearly demonstrated that 
increased Aβ oligomers production lead to the activation of neuronal TNF-α 
receptor and the aberrant activation of stress-regulated kinases [i.e. Jun N-
terminal kinase (JNK), I kappa B kinase (IKK), and protein kinase R (PKR)] 
[216, 235] and endoplasmic reticulum (ER) stress (PKR-mediated 
phosphorylation of eIF2α-P) [235], which leads to IRS1 inhibition. This 
implies a role for Aβ-mediated neuroinflammation in the development of 
brain insulin resistance independently from a systemic insulin resistant state.   
Our previous results collected in the hippocampus of 3xTg-AD mice 
further support the idea that alterations of insulin signalling cascade can 
develop independently from peripheral insulin resistance. We identified the 
reduced activation of BVR-A as an early molecular event favoring the 
development of brain insulin resistance since it occurs before a significant 
inhibition of IRS1 [141]. In particular, in a longitudinal study conducted in 
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3xTg-AD mice we identified an early phase characterized by reduced BVR-A 
activation and IRS1 hyper-activation (at 6 months of age) and a late phase in 
which the persistent reduction of BVR-A activity was associated with a 
significant inhibition of IRS1 and thus brain insulin resistance (at 12-18 
months of age) [141]. Changes of BVR-A and insulin signalling in the brain 
precede significant alterations of glucose tolerance in 3xTg-AD [236, 237]. 
Furthermore, we also found that reduced BVR-A activation was evident 
before a consistent rise in Aβ levels and a significant elevation of TNF-α 
[141] in the hippocampus, thus representing an early event.  
All together these evidences support the role of brain insulin 
resistance in the progression of AD neuropathology, although the 
mechanisms through which brain insulin resistance develops or is sustained, 
could be different.  
Interestingly, also in this study, we found that the impairment of the 
insulin signalling cascade – which is characterized by the typical signs of 
brain insulin resistance observed in human AD (i.e., reduced IR and Akt 
activation and increased GSK-3β inhibition [180-183]) – occurs earlier than 
either (i) Aβ accumulation in the parietal cortex (for additional studies in 
dogs see also [160, 238]) or (ii) significant manifestations of cognitive 
decline in beagles [239], thus representing an antecedent event. Moreover, 
alterations of insulin signalling occur even before a consistent elevation of 
pro-inflammatory processes in the brain, which has been demonstrated to 
develop mainly after 8 years of age in beagles [240-245].  
We are aware that one limitation of our study is the lack of any 
metabolic information (i.e. fasting glucose or insulin levels) about the 
animals used. Indeed, we cannot completely exclude that an altered metabolic 
profile in these dogs could impact on the molecular changes observed in the 
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brain. However, as previously reported in 2 longitudinal studies [246, 247], 
beagles show significant alterations of serum chemistry values possibly 
referring to an altered metabolic profile (i.e., fasting glucose, triglycerides, 
ALT, AST) only after 9 years of age. These evidences, therefore, could 
support our idea about the development of brain insulin resistance 
independently from peripheral metabolic changes since the first alterations 
we have found are evident already at 4 years in the parietal cortex. 
The observed dysfunction of BVR-A most probably favours these 
alterations since it occurs in parallel with the reduction of IR and Akt 
activation, in agreement with our and others previous results. Indeed, BVR-A 
regulates both IR and Akt activation in vitro [174, 198]. Loss of BVR-A 
triggers the development of both brain [141] and systemic [248, 249] insulin 
resistance in mice.  BVR-A kinase activity is also disrupted in human post-
mortem hippocampus of both MCI and AD cases [171, 172] and is reduced 
in plasma collected from MCI and AD patients [184]. Furthermore, we 
demonstrated that insulin treatment (100 nM) promote the inhibition of IRS1 
instead of the activation of the insulin signalling cascade in neuronal cells 
lacking BVR-A [141]. Similarly, we found a consistent reduction of BVR-A 
activation in cells in which we induced insulin resistance [141]. 
Reduced BVR-A activation in the parietal cortex in dogs, appears to 
be mainly driven by a reduction of Tyr residue phosphorylation as observed 
in young 3xTg-AD mice [141], whereas a significant oxidative/nitrosative 
stress-induced increase of 3-NT on BVR-A occurs at a late stage as we 
observed in human AD [171]. This observation, highlight the role of 
oxidative/nitrosative stress as a factor contributing to the alterations of the 
insulin signalling in the brain. While at the beginning low/mild levels of 
nitrosative stress contribute to BVR-A dysfunction, the consequent 
impairment of insulin signalling cascade can even favor the significant 
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increase of total 3-NT levels as observed in our samples with age. Indeed, 
insulin signalling plays a pivotal role in the maintenance of mitochondrial 
functions normally deputed to energy production [250-252]. Therefore, the 
development of brain insulin resistance would promote mitochondrial 
dysfunctions responsible for reduced energy production, in turn associated 
with an increase of reactive oxygen/nitrogen species formation, finally 
leading to the oxidative/nitrosative damage of mitochondria as well as other 
cellular components [253].  
Of note, the impairment of BVR-A not only alters the physiological 
activation of the insulin signalling but also precedes the accumulation of β-
amyloid peptide in the parietal cortex, thus further strengthening our 
hypothesis that the role of this protein is to serve as a molecular link bridging 
brain insulin resistance and Aβ production. Results collected in vitro support 
this mechanism since HEK293APPsw cells silenced for BVR-A show 
increased Aβ production when stimulated with a physiological dose of 
insulin. Moreover, data from beagles are in agreement with data collected in 
3xTg-AD mice where the impairment of BVR-A was observed before a 
significant Aβ accumulation in the hippocampus was observed [141]. 
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Figure 16. Hypothesized mechanism through which impairment of BVR-A links brain 
insulin resistance with increased Aβ production in AD. Under physiological conditions 
insulin receptor (IR) phosphorylates biliverdin reductase-A (BVR-A) on tyrosine (Y) 
residues promoting BVR-A kinase activity [187]. Through this kinase activity BVR-A 
regulates the activation of insulin receptor substrate-1 (IRS1) by phosphorylating IRS1 on 
Ser (S) residues, which normally inhibit IRS1 activation. In this way, BVR-A prevents IRS1 
hyper-activation. In parallel, BVR-A favors the activation of protein kinase B (Akt), which 
inhibits the activation of glycogen synthase kinase-3β (GSK-3β) while promotes the 
activation of mammalian target of rapamycin (mTOR). Here, we suggest that BVR-A 
activation plays a critical role also in the regulation of beta secretase 1 (BACE1) recycling to 
the plasma membrane. The proposed path probably occurs at the level of the early 
endosomes where casein kinase 1(CK1)-mediated Ser phosphorylation of BACE1 favors 
BACE1 recycling to plasma membrane [188, 189]. We suggest that during the progression of 
Alzheimer disease (AD) pathology the early dysfunction of BVR-A (1) impairs the 
activation of the insulin signalling cascade and in parallel (2) promotes CK1-mediated 
BACE1 recycling at the plasma membrane, where BACE1 cleaves amyloid precursor protein 
(APP), leading to increased beta amyloid (Aβ) production. In turn, in a vicious cycle, 
increased Aβ oligomers trigger the elevation of oxidative and nitrosative stress levels, which 
further impair BVR-A. Arrows, activation; dotted lines, inhibition. Red arrows/lines, BVR-A 
functions impaired in AD. 
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PROJECT 2  
 
6. RESULTS  
 
 6.1. Intranasal insulin administration improves short-term 
learning and memory in 6- and 12-month-old 3×Tg-AD mice. 
 
We tested the effects of insulin treatment on both short- and long-term 
memory in both 6- and 12-month-old 3×Tg-AD mice and age-matched WT 
littermates, performing hippocampal- and cortical-dependent tasks as 
measured by morris water maze (MWM) and novel object recognition (NOR) 
tests. Spatial learning and memory were measured by MWM, in which mice 
received 4 training trials/day for 5 consecutive days to locate the hidden 
platform. Statistics demonstrated no difference in spatial memory during 5 
days of training (acquisition) among all experimental groups at 6 and 12 
months of age, indicating there is no difference in motivation or ability to 
perform the task (Fig. 17B). To determine the effects of insulin on memory, 
the platform was removed from the maze, and tests were conducted 1.5 or 24 
h following the last training trial to independently assess both short- and 
long-term memory, respectively. Insulin significantly rescued the short-term 
(1.5 h) spatial memory deficits present in both 6- and 12-month-old 3×Tg-
AD mice, as indicated by a significantly decreased latency to cross the 
platform location and increased time spent in target quadrant of the 3×Tg-AD 
mice treated with insulin compared to vehicle-treated 3×Tg-AD (Figures 17C 
and D). Moreover, insulin had no significant effects on learning or memory 
retention in WT mice. When a probe session was performed at 24 hours 
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(long-term memory) after the last training session, at 6 months of age, insulin 
induced only a trend toward a decrease (-32%) in the 3×Tg-AD compared to 
vehicle-treated 3×Tg-AD mice (Fig. 17C); conversely, the latency to cross 
platform location was significantly decreased (-58%) at 12 months of age in 
insulin-treated 3×Tg-AD mice compared to age-matched vehicle-treated 
3×Tg-AD mice (Fig. 17C). Regarding the time spent in the target quadrant at 
24 h after the last training session, insulin induced only a trend toward an 
increase in the 3×Tg-AD compared to vehicle-treated 3×Tg-AD mice (+35% 
and +52%, respectively, at 6 and 12 months of age) (Fig. 17D). Finally, 
multiple post-hoc comparisons showed that 3×Tg-AD mice treated with 
insulin performed similarly to the WT mice in all probe trials and at both 
time-points.  
The NOR test exploits the natural tendency of mice to explore objects 
perceived as novel. As previously described, the retention session was 
performed at two different time points (30 min or 24 h) after the exploration 
session in order to assess both short- and long-term memory, respectively. 
Two-way ANOVA for the object recognition index (ORI) at a time-point of 
30 min (short-term memory) either in 6- and 12-month-old mice revealed a 
significant main effect of genotype and treatment, while no significant 
genotype-by-treatment interaction effect was found. Multiple post-hoc 
comparisons showed a significant higher ORI in insulin-treated 3×Tg-AD 
with respect to vehicle-treated 3×Tg-AD mice, indicating that insulin 
significantly improves the short-term recognition memory in the 3×Tg-AD 
mice (Fig. 19E). When the probe trial was performed 24 h after the 
exploration session (long-term memory), we observed only a significant main 
effect of genotype among the four groups (Fig. 17E). Although insulin-
treated 3×Tg-AD mice performed better than vehicle-treated 3×Tg-AD mice, 
multiple post-hoc comparisons did not reach any significant difference 
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(+26% and +21%, respectively, at 6 and 12 months of age). Finally, at both 
time points, the post-hoc analysis indicated that insulin had no effect on the 
performance of WT mice. 
Overall, these data indicate that insulin significantly both prevents 
and rescues the impairment of the short-term memory in either 6- and 12-
month-old 3×Tg-AD mice, respectively with no significant effects on long-
term memory. Moreover, insulin apparently exerts no significant effects on 
learning or memory in both adult and aged WT mice. 
 
 
6.2  Intranasal insulin administration ameliorates the 
depressive-like behaviour in 3×Tg-AD mice. 
 
Depressive-like behaviours were measured by the tail suspension test 
(TST) and forced swim test (FST). Statistical details are reported in Table 1. 
At 6 and 12 months of age, significant main effects of treatment, genotype, 
and genotype-by-treatment interactions were observed, except for the 
interaction in the older group of animals. As previously demonstrated [165, 
166], post-hoc comparisons revealed that the immobility time in both tests 
was higher in vehicle-treated 3×Tg-AD than in vehicle-treated WT mice (Fig. 
17F&G). Moreover, insulin significantly decreased the immobility time in 
the 3×Tg-AD mice for both tests, either at 6 and 12 months of age (Fig. 
17F&G).  
Taken together, these results confirm that 3×Tg-AD mice show a 
depressive-like phenotype, which is reversed by insulin treatment at 6 and 12 
months of age. Moreover, insulin has no significant effect on WT mice. 
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Figure 17. Insulin rescues short-term memory deficits and ameliorates the depressive-
like phenotype in the 3×Tg-AD mice. (A) Schematic representation of the experimental 
design. Evaluation of the cognitive (B-E) and emotional phenotype (F and G) of 6- and 12-
month-old 3×Tg-AD and age-matched Non-Tg mice chronically treated with vehicle or 
insulin. Short- and long-term memory of mice was evaluated (B-D) by Morris water maze 
(MWM) and (E) novel object recognition (NOR) test (NORT). Moreover, the emotional 
phenotype of mice was evaluated by (F) forced swimming test (FST) and (G) tail suspension 
test (TST). Sample size is indicated in the bars. Data are presented as means ± SEM. 
Statistical analysis was performed by two-way ANOVA followed by Tukey’s multiple 
comparison test (*p < 0.05; **p < 0.01; ***p < 0.001). 
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6.3 Intranasal insulin administration prevents the 
impairment of BVR-A and the early dysfunction of the insulin 
signalling cascade in adult 3×Tg-AD mice at 6 months of age. 
 
According to our hypothesis, the impairment of BVR-A is associated 
with the dysfunction of the insulin signalling cascade, which contributes to 
the cognitive impairment observed in AD [181, 196]. However, no data exist 
about the role of BVR-A in the hippocampal synaptic plasticity. To 
investigate this aspect, we studied long-term potentiation (LTP) at CA3–CA1 
synapses in hippocampal organotypic slices biolistically transfected with 
shRNA for BVR-A together with a plasmid enconding enhanced green 
fluorescent protein (EGFP) to identify the transfected neurons (Fig. 
18A). Silencing of BVR-A significantly reduced the LTP magnitude at CA3-
CA1 synapses compared with LTP observed in neurons transfected with a 
scrambled shRNA (shLuc=261+/-92.4% versus shBVR-A=176.9 +/-66.8%, 
p  =  0.049; Fig. 20B).  
These data demonstrate for the first time that BVR-A has a role in the 
hippocampal synaptic plasticity and therefore its impairment in AD could be 
crucial to mediate cognitive and learning dysfunctions.  
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Figure 18. Hippocampal LTP was inhibited in organotypic brain slices in which BVR-A 
was silenced. (A) Schematic representation of whole-cell recording from CA1 hippocampal 
pyramidal neuron in organotypic hippocampal slice (see methods for details). (B) Time 
course of LTP at CA3-CA1 synapses in hippocampal organotypic slices transfected with 
BVR-A shRNA or scrambled shRNA. Results are expressed as percentages of baseline 
EPSC amplitude (=100%). Insets (top) show representative EPSC at baseline (1) and during 
the last 5  min of LTP recording (2). C) Mean LTP values during the last 5  min (n  =  7-
8/group). Data are expressed as mean  ±  SEM *p  <  0.05. 
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To determine whether INI administration was effective in preventing 
the impairment of BVR-A and the early alterations of the insulin signalling 
cascade observed in 3×Tg-AD mice at 6 months of age [141], here we 
evaluated changes of (i) BVR-A protein levels and Tyr phosphorylation 
together with (ii) the levels and activation of some main components of the 
insulin signalling cascade in the hippocampus and cortex of 3×Tg-AD mice 
and their littermate WT controls, treated with vehicle or insulin for 2 months 
(from 4 to 6 months of age).  First, we confirmed our previous results 
showing reduced BVR-A levels and activation in the hippocampus of 6-
month-old vehicle-treated 3×Tg-AD mice compared to vehicle-treated WT 
mice (Fig. 19A-C). INI treatment did not affect BVR-A protein levels (Fig. 
19A&C), while INI was effective in preventing the observed impairment of 
BVR-A activation in 3×Tg-AD mice (Fig. 19B&C). No significant changes 
were observed between INI-treated and vehicle-treated WT mice (Fig. 19A-
C).  
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Figure 19. Intranasal insulin prevents the early impairment of BVR-A in the 
hippocampus of 3×Tg-AD mice at 6 months of age. (A-B) Immunoblot analysis and (C) 
densitometric evaluation of changes of BVR-A protein levels and Tyr-phosphorylation 
(pTyr) observed in the hippocampus of 3×Tg-AD mice and WT littermate controls treated 
with vehicle (vehic) or insulin from 4 to 6 months of age. Densitometric values shown are 
given as percentage of WT vehic mice set as 100%. BVR-A protein levels were normalized 
per total protein load. pTyr levels on BVR-A were normalized by using total BVR-A as 
loading control following immunoprecipitation [169, 170]. Data are presented as means ± 
SEM (n=6 mice/group). Statistical analysis was performed by Two-way ANOVA followed 
by Bonferroni’s multiple comparison test (*p < 0.05).  
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Consistent with our hypothesis, the activation of BVR-A, induced by 
INI treatment, resulted in a significant improvement of the insulin signalling 
cascade in the hippocampus of 3×Tg-AD mice (Fig. 20). In particular, we 
found that INI further stimulated IR activation (pIRTyr1158/1161/1162/IR) in adult 
3×Tg-AD mice compared to age-matched vehicle-treated 3×Tg-AD mice, 
leaving unchanged the IR protein levels (Fig. 20B&C). Moreover, we 
evaluated the activation of IRS1 by analysing the levels of two of the best 
characterized sites known to promote IRS1 inhibition and thus insulin 
resistance even in AD brain: Ser307 and Ser636 [181, 197]. INI did not 
induce changes of IRS1 levels, while INI prevented the pathological hyper-
activation of IRS1 in 3×Tg-AD mice, as demonstrated by the extent of IRS1 
inhibition (mostly pIRS1Ser636/IRS1), which returns close to those observed 
for WT mice (Fig. 20B&D). Rescue of the BVR-A/IRS1 axis activation was 
reflected by the activation of the downstream targets. Here, we extended our 
previous findings [141] by showing that ERK1/2 levels did not change across 
all the experimental groups, while their activation was significantly increased 
in the hippocampus of vehicle-treated 3×Tg-AD mice and it was partially 
reduced (∼70%, p=0.07) following INI administration (Fig. 20B&E). Further, 
we found that Akt protein levels in the hippocampus of 3×Tg-AD mice were 
significantly increased compared to vehicle-treated WT mice, and were not 
affected by INI treatment (Fig. 20B&F); conversely, Akt activation was 
strongly stimulated following insulin administration in 3×Tg-AD mice 
compared to vehicle-treated group (pAktSer473/Akt, Fig. 20B&F). The 
improvement of Akt activation was associated with the amelioration of 
mTOR activation, whose reduction was prevented in INI-treated 3×Tg-AD 
mice (p-mTORSer2448/mTOR, Fig. 20B&G). Keeping in mind the role of 
BVR-A in regulating insulin signalling at different levels [187, 198, 199], 
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these observations further support our hypothesis that the impairment of 
BVR-A is associated upstream with the hyper-activation of the IR/IRS1 axis, 
while downstream with an aberrant activation of MAPK and Akt/mTOR 
axes. Instead, INI treatment prevents the alterations of BVR-A and 
ameliorates the entire activation of the insulin signalling in the hippocampus 
of adult 3×Tg-AD mice. 
In WT mice, INI treatment led to a significant increase of the IR 
activation (Fig. 20C) – indicating the stimulatory effect of administered 
insulin – which, was associated with a reduction of IRS1 Ser636 
phosphorylation (∼40%, p=0.06, Fig. 20D), along with a significant increase 
of ERK1/2 activation (Fig. 20E). No changes of the Akt/mTOR pathway 
were observed in the hippocampus of INI-treated WT mice with respect to 
vehicle-treated WT mice (Fig. 20F&G). This is in agreement with the well-
known possibility that the two main harms of the insulin signalling cascade, 
i.e., the MAPK and the Akt pathways, are not stimulated simultaneously 
[200, 201].  
Taken together, these lines of evidence suggest that the impairment of 
BVR-A occurs early along the progression of AD pathology in 3×Tg-AD 
mice and is associated with a dysfunction of the insulin signalling cascade 
mainly in the hippocampus, which can be significantly prevented by INI 
administration. 
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Figure 20. Intranasal insulin promotes IR activation and prevents the early impairment 
of the insulin signalling cascade in the hippocampus of 3×Tg-AD at 6 months of age. (A) 
Schematic representation of the insulin signalling cascade. Blue arrows: activation; red line: 
inhibition; Y: tyrosine residues; S: serine residues.  (B) Immunoblot analysis and (C-G) 
densitometric evaluation of IR, IRS1, ERK1/2, Akt and mTOR protein levels and 
phosphorylation measured in the hippocampus of 3×Tg-AD mice and in WT littermate 
controls treated with vehicle (vehic) or insulin from 4 to 6 months of age. Densitometric 
values shown are given as percentage of WT vehic mice set as 100%. Protein levels were 
normalized per total protein load. Proteins’ phosphorylation was normalized by taking into 
account the respective protein levels and are expressed as the ratio between the 
phosphorylated form and the total protein levels: pIR(Tyr1158/1162/1163)/IR, pIRS1(Ser307 or 
Ser636)/IRS1, pERK1/2(Thr202/Tyr204)/ERK1/2, pAkt(Ser243)/Akt, pmTOR(Ser2448)/mTOR. Data are 
presented as means ± SEM (n=6 mice/group). Statistical analysis was performed by Two-
way ANOVA followed by Bonferroni’s multiple comparison test (*p < 0.05, **p < 0.01). 
 
	   100	  
6.4 Intranasal insulin administration recovers BVR-A 
activation and prevents the onset of brain insulin resistance in 
aged 3×Tg-AD mice at 12 months of age. 
 
To further characterize the molecular mechanisms underlying the 
beneficial effects of INI, we evaluated whether insulin treatment (from 10 to 
12 months) was effective in recovering the activation of BVR-A and thus 
preventing the onset of brain insulin resistance in aged (12 months) 3×Tg-AD 
mice [141].  
In agreement with what we observed with adult (6 months) 3×Tg-AD 
mice, INI administration to aged 3×Tg-AD mice did not promote changes of 
brain BVR-A protein levels, which remained reduced even after the 
treatment, whereas INI significantly recovered the activation of BVR-A in 
the hippocampus of aged 3×Tg-AD mice (Fig. 21C). Unexpectedly, INI 
treatment promoted a significant reduction of BVR-A activation in the 
hippocampus of WT mice compared to the vehicle-treated WT mice (Fig. 
21C).  
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Figure 21. Intranasal insulin recovers BVR-A activation in the hippocampus of 3×Tg-
AD mice at 12 months of age. (A-B) Immunoblot analysis and (C) densitometric evaluation 
of changes of BVR-A protein levels and Tyr-phosphorylation (pTyr) observed in the 
hippocampus of 3×Tg-AD mice and WT littermate controls treated with vehicle (vehic) or 
insulin from 10 to 12 months of age. Densitometric values shown are given as percentage of 
WT vehic mice set as 100%. BVR-A protein levels were normalized per total protein load. 
pTyr levels on BVR-A were normalized by using total BVR-A as loading control following 
immunoprecipitation [169, 170]. Data are presented as means ± SEM (n=6 mice/group). 
Statistical analysis was performed by One-way ANOVA followed by Bonferroni’s multiple 
comparison test (*p < 0.05; **p < 0.01). 
 
	   102	  
The evaluation of the insulin signalling cascade revealed that INI 
administration did not promote an increase of IR protein levels (Fig. 
22A&B), while INI led to a consistent activation of the IR in the 
hippocampus of aged 3×Tg-AD mice compared to vehicle-treated 3×Tg-AD 
mice (Fig. 22A&B). With regard to IRS1 activation, here we strengthened 
our previous findings [141] by also showing a significant elevation of IRS1 
Ser636 phosphorylation (Fig. 22A&C), which, together the observed 
impairment of the IR, are indicative of a condition of brain insulin resistance. 
INI significantly reduced the levels of IRS1 Ser636 phosphorylation in 3×Tg-
AD mice, which were reported close to those of vehicle-treated WT mice 
(Fig. 22A&C). Downstream from IR, the amelioration of the BVR-A/IRS1 
axis positively did impact on both ERK1/2 and Akt pathways in the 
hippocampus of aged 3×Tg-AD mice. Although we did not find changes for 
ERK1/2 or Akt protein levels (Fig. 22D&E), we found significant differences 
in terms of their activation. Indeed, the insulin resistance phenomenon was 
associated with no changes of ERK1/2 activation (Fig. 22D), but a consistent 
impairment of Akt activation in the hippocampus of vehicle-treated 3×Tg-
AD mice was found (Fig. 22E). Strikingly, INI was effective in promoting 
the activation of both ERK1/2 (Fig. 22A&D) and Akt (Fig. 22A&E) proteins, 
thus indicating an improved insulin signalling activation. Downstream from 
Akt, we did not observe changes for mTOR protein levels and activation in 
aged 3×Tg-AD mice following INI treatment (Fig. 22F). However, by 
considering that IRS1 Ser636 is a direct target of mTOR when aberrantly 
activated [197], it seems that INI administration ameliorates the regulation of 
the Akt/mTOR axis finally resulting in a reduction of IRS1 Ser636 
phosphorylation. 
 
	   103	  
In WT mice, insulin administration promoted the activation of the IR 
without significant changes of the downstream targets, except for Akt whose 
activation was significantly reduced (Fig. 22A&E). Other than Akt, we also 
noticed an augmentation mTOR activation (∼78%, p=0.08, Fig. 22A&F), 
which, together with reduced BVR-A activation, could be representative of 
an impairment of the insulin signalling cascade. These results, therefore, 
possibly suggest that insulin, if administered for long time to an adult brain 
that is not compromised, could favour/accelerate the impairment of insulin 
signalling [as shown by [202-204].   
Overall, these results suggest that INI administration improves the 
activation of BVR-A and prevents the onset of brain insulin resistance in the 
brain of aged 3×Tg-AD mice.  
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Figure 22. Intranasal insulin promotes IR activation and prevents the onset of brain 
insulin resistance in the hippocampus of 3×Tg-AD at 12 months of age. (A) Immunoblot 
analysis and (B-F) densitometric evaluation of IR, IRS1, ERK1/2, Akt and mTOR protein 
levels and phosphorylation measured in the hippocampus of 3×Tg-AD mice and in WT 
littermate controls treated with vehicle (vehic) or insulin from 10 to 12 months of age. 
Densitometric values shown are given as percentage of WT vehic mice set as 100%. Protein 
levels were normalized per total protein load. Proteins’ phosphorylation were normalized by 
taking into account the respective protein levels and are expressed as the ratio between the 
phosphorylated form and the total protein levels: pIR(Tyr1158/1162/1163)/IR, pIRS1(Ser307 or 
Ser636)/IRS1, pERK1/2(Thr202/Tyr204)/ERK1/2, pAkt(Ser243)/Akt, pmTOR(Ser2448)/mTOR. Data are 
presented as means ± SEM (n=6 mice/group). Statistical analysis was performed by Two-
way ANOVA followed by Bonferroni’s multiple comparison test (*p < 0.05, **p < 0.01). 
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6.5 BVR-A is required for the correct transduction of the 
insulin signalling cascade in vitro. 
 
To investigate whether BVR-A activation is essential to mediate the 
beneficial effects of the INI administration in 3×Tg-AD mice, we performed 
several in vitro experiments aimed to demonstrate that insulin’s ability to 
recover cells from insulin resistance requires BVR-A.  First, we tested 
whether insulin (100 nM) at different times (2-6-12-24 h) promotes the 
activation of its downstream targets in controls cells and in cells in which 
BVR-A had been silenced (to mimic a condition in which BVR-A does not 
work). We found that insulin leads to the activation of ERK1/2 and Akt only 
in control cells (Fig. 23F&H, respectively). In siRNA-treated cells insulin 
failed to promote its downstream effects. Rather, insulin treatment favours 
the inhibitory phosphorylation of IRS1 along with suppression of ERK1/2 
and Akt activation (Fig. 23F&H, respectively).  These results, therefore, 
indicate that BVR-A is required to mediate the correct transduction of the 
insulin signalling cascade, which otherwise would be shifted toward a 
condition of insulin resistance.  
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Figure 23. BVR-A is required to mediate the correct activation of the IS cascade in 
vitro. (A) Immunoblot analysis and (C-G) densitometric evaluation of BVR-A, IRS1, 
ERK1/2 and Akt protein levels along with their activation evaluated in HEK cells following 
insulin treatment at different times. Numbers in panel (B) and those indicated in each column 
of the densitometric analysis are matched. Densitometric values shown are given as 
percentage of control cells (column 1) set as 100%. Protein levels were normalized per total 
protein load. Proteins’ phosphorylation were normalized by taking into account the 
respective protein levels and are expressed as the ratio between the phosphorylated form and 
the total protein levels: pIRS1(Ser636)/IRS1, pERK1/2(Thr202/Tyr204)/ERK1/2 and pAkt(Ser243)/Akt. 
Data are presented as means ± SEM (n=3 independent cultures/group). *p < 0.05 (Student t-
test). 
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Based on these data and due to the fact that Akt was the main target 
modulated by the INI administration in 3×Tg-AD mice, we selected 2 h as 
time for treatment to use in the subsequent experiments. As shown in Fig. 
24A, we set up a protocol in which, first we induced insulin resistance and 
then we tried to recovery insulin signalling activation both in control and 
siRNA-treated cells, by re-challenging these cells with increasing doses of 
insulin (to mimic the effect of the INI administration).  
Indeed, we found that insulin (100 nM, for 2h) promoted the 
activation of IR, Akt and mTOR in control cells (Fig. 24C-G, column 4), 
whereas a significant increase of IRS1 inhibition (Fig. 24D, column 5), a 
reduction of Akt activation (Fig. 24F, column 5) and a sustained activation of 
mTOR (Fig. 24G, column 5) were observed when we induced insulin 
resistance by over-exposing these cells to additional insulin (100 nM, for 
additional 2h). Similar changes were found in siRNA-treated cells where 
insulin treatment (100 nM, 2 h) directly promoted insulin resistance (Fig. 
24C-G, column 9). At this point, both control and siRNA-treated cells were 
re-challenged with fresh medium containing increasing doses of insulin (100 
nM-500 nM-1 µM, for 2 h) to test whether insulin was able to recover the 
activation of the insulin signalling cascade. We found that insulin, at all the 
concentrations tested, further increased the activation of IR both in control 
(Fig. 24C, columns 6-8) and siRNA-treated cells (Fig. 24C, columns 10-12).  
Notwithstanding this result, we observed a difference in terms of activation 
of the downstream targets. In control cells, among the tested doses, insulin at 
500 nM was able to partially recover the activation of Akt (Fig. 24F, column 
7), thus possibly indicating an amelioration of the insulin signalling cascade. 
Conversely, neither of the tested doses was effective in promoting Akt 
activation in siRNA-treated cells (Fig. 24F, columns 10-12). Increased Akt 
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activation was also associated with a reduction of mTOR activation in control 
cells (Fig. 24G, column 7). Instead, a persistent mTOR activation even 
further elevated at the highest dose of insulin (1 µM) was observed in cells in 
which BVR-A was silenced (Fig. 24G, columns 10-12).  
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Figure 24. BVR-A is required recovery insulin signalling activation in vitro. (A) Scheme 
of the protocol used to induce the activation of the insulin signalling as well as insulin 
resistance in HEK cells (for details see Material and Methods). For each condition, numbers 
in plain circle indicate the treatment while those in empty circle are relative the collection 
time. (B) Immunoblot analysis and (C-G) densitometric evaluation of BVR-A, IR, IRS1, 
ERK1/2, Akt and mTOR activation evaluated following different insulin treatments in 
control HEK cells or in cells in which BVR-A was silenced through a specific siRNA. 
Numbers in panel (B) and those indicated in each column of the densitometric analysis are 
matched and are indicative of the treatment performed as also indicated in (A). 
Densitometric values shown are given as percentage of control cells (column 1) set as 100%. 
Protein levels were normalized per total protein load. Proteins’ phosphorylation were 
normalized by taking into account the respective protein levels and are expressed as the ratio 
between the phosphorylated form and the total protein levels: pIR(Tyr1158/1162/1163)/IR, 
pIRS1(Ser636)/IRS1, pERK1/2(Thr202/Tyr204)/ERK1/2, pAkt(Ser243)/Akt, pmTOR(Ser2448)/mTOR. 
Data are presented as means ± SEM (n=3 independent cultures/group). *p < 0.05 (Student t-
test). 
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To further confirm the pivotal role of BVR-A, we took advantage of 
the use of the BVR-A- mimetic peptide 290KYCCSRK, which has been 
previously demonstrated to mimic the kinase activity of BVR-A toward the 
IR/IRS1 axis thus favoring the activation of the insulin signalling cascade 
[174, 205].  Strikingly, we found that insulin (100 nM, for 2h) did not induce 
insulin resistance if administered together with the peptide (10 and 20 µM) in 
siRNA-treated cells (Fig. 27, columns 5-7).  The treatment with the peptide at 
both the tested doses favors the activation of the insulin signalling cascade as 
demonstrated by the significant reduction of IRS1 inhibition (Fig. 25D, 
columns 6-7), the increase of both ERK1/2 (Fig. 25E, coulmns 6-7) and Akt 
activation (Fig. 25F, columns 6-7) and the reduction of mTOR activation 
(Fig. 25G, columns 6-7).  Furthermore, the peptide allows recovery of 
siRNA-treated cells from insulin resistance (Fig. 25, columns 8-10). Indeed, 
while insulin alone is not able to recover insulin signalling activation, insulin 
does if administered together with the peptide, which leads to a significant 
reduction of IRS1 inhibition (Fig. 25D, columns 8-10) along with a 
significant activation of Akt (Fig. 25F, columns 8-10) and a reduction of 
mTOR activation (Fig. 25G, columns 8-10). 
Overall these findings demonstrate the central role that BVR-A plays 
in the regulation of the insulin signalling cascade and also strengthen the 
notion of the role played by BVR-A in the molecular mechanisms underlying 
the beneficial effects of the INI administration.  
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Figure 25. The BVR-A mimetic peptide 290KYCCSRK recovers the correct activation of 
the insulin signalling cascade in cells lacking BVR-A. (A) Scheme of the protocol used to 
treat cells (for details see Material and Methods). For each condition, numbers in plain circle 
indicate the treatment while those in empty circle are relative the collection time. (B) 
Immunoblot analysis and (C-G) densitometric evaluation of BVR-A, IR, IRS1, ERK1/2, Akt 
and mTOR activation evaluated in control cells or in cells silenced for BVR-A and treated 
with insulin alone or in combination with the 290KYCCSRK peptide (P). Numbers in panel 
(B) and those indicated in each column of the densitometric analysis are matched and are 
indicative of the treatment performed as also indicated in (A). Densitometric values shown 
are given as percentage of control cells (column 1) set as 100%. Protein levels were 
normalized per total protein load. Proteins’ phosphorylation were normalized by taking into 
account the respective protein levels and are expressed as the ratio between the 
phosphorylated form and the total protein levels: pIR(Tyr1158/1162/1163)/IR, pIRS1(Ser636)/IRS1, 
pERK1/2(Thr202/Tyr204)/ERK1/2, pAkt(Ser243)/Akt, pmTOR(Ser2448)/mTOR. Data are presented as 
means ± SEM (n=3 independent cultures/group). *p < 0.05 and **p < 0.01 (Student t-test). 
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6.6 Amelioration of insulin signalling activation is 
associated with reduced oxidative stress levels and AD 
neuropathological markers in the hippocampus and cortex 
of INI-treated 3×Tg-AD mice. 
 
We previously reported that the dysregulation of the insulin signalling 
cascade in the hippocampus of 3×Tg-AD mice was associated with increased 
oxidative/nitrosative stress levels as well as a worsening of AD-like 
neuropathology [141]. To further explore whether the improved functionality 
of the insulin signalling cascade following INI administration might affect 
the above-mentioned pathological features of AD brain, we evaluated 
changes of oxidative/nitrosative stress markers, Aβ oligomers and Tau levels, 
and phosphorylation in the hippocampus and cortex of WT and 3×Tg-AD 
mice both at 6 and 12 months of age.  
We found that INI treatment significantly reduced 3-NT levels in the 
hippocampus both in adult  (Fig. 26A) and aged (Fig. 26D) 3×Tg-AD mice. 
In parallel, western blot analysis revealed that INI treatment did not 
significantly modify the expression of full-length APP and Aβ dodecamer 
(Aβ*56) either in the hippocampus of 6-month-old insulin-treated 3×Tg-AD 
mice (Fig. 26B&C). Rather, we observed a significant reduction of Aβ 
oligomers in hippocampus (Fig. 26E&F) of 12-month-old 3×Tg-AD. To 
better understand the mechanisms responsible for the observed reduction of 
Aβ in the hippocampus of 3×Tg-AD mice following INI administration, we 
analysed the expression levels of the insulin-degrading enzyme (IDE), known 
to be involved in the degradation of Aβ [206]. Regardless of the age of the 
mice, we observed no significant changes in the expression levels of IDE 
either in the hippocampus of 3×Tg-AD mice after INI administration (Fig. 
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26B&F) thus suggesting that probably other degradative or clearance 
mechanisms are responsible for the observed reduction of Aβ oligomers. 
Finally, we found that INI administration was able to ameliorate Tau 
pathology both in hippocampus and frontal cortex of 3×Tg-AD mice. In 
particular, we observed reduced phosphorylation levels of tau protein on 
Ser202/Thr205 residues in the hippocampus of adult (Fig. 26B&C) and aged 
(Fig. 26E&F) 3×Tg-AD mice.  
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Figure 26. Improvement of insulin signalling cascade activation following insulin 
administration is associated with reduced nitrosative stress levels and an improvement 
of AD neuropathology in the hippocampus of 3×Tg-AD mice. Changes of oxidative 
(HNE) and nitrosative (3-NT) stress levels evaluated in the hippocampus of 3×Tg-AD mice 
and WT littermate controls treated with vehicle (vehic) or insulin from 4 to 6 months (A) and 
from 10 to 12 months (D) of age. Data are presented as means ± SEM (n=6 mice/group). 
Statistical analysis was performed by Two-way ANOVA followed by Bonferroni’s multiple 
comparison test (*p < 0.05, **p < 0.01). (B and E) Immunoblot analysis and (C and F) 
densitometric evaluation of changes of full-length APP, Aβ dodecamer (Aβ*56), Tau 
phosphorylation and IDE measured in the hippocampus of 3×Tg-AD treated with vehicle or 
insulin from 4 to 6 months (B and C) and from 10 to 12 months (E and F) of age.  For 
oxidative/nitrosative stress markers values shown are given as percentage of WT vehic mice 
set as 100%. Densitometric values shown are given as percentage of 3×Tg-AD vehic mice 
set as 100%. Protein levels were normalized per total protein load. Tau phosphorylation was 
normalized by taking into account the respective protein levels and are expressed as the ratio 
between the phosphorylated form and the total protein levels: pTau(Ser202/Thr205)/Tau. Data are 
presented as means ± SEM (n=6 mice/group) *p < 0.05 (Student t-test) 
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7. Discussion 
 
With a long prodromal period of 10 to 20 years, AD and related 
dementias are becoming a priority for many governments, considering that 
1% of global gross domestic product is spent on dementia care [254]. Brain 
insulin resistance greatly contributes to this preclinical period during which 
only subtle behavioral symptoms are evident [158], and no reliable 
biomarkers indicative of any potential risks are available [255]. Therefore, 
the comprehension of the initiating molecular events leading to brain insulin 
resistance is fundamental to strengthen the set-up of new prevention 
strategies aimed to reduce both the risks and the dramatic outcomes of 
metabolic dysfunctions in the brain.   
To better characterize the molecular mechanisms underlying the 
alterations of brain insulin signalling, we focused on the protein BVR-A 
[187], whose impairment was demonstrated to precede the canonical 
molecular alterations associated with the insulin resistance phenomenon, i.e., 
reduced IR or increased IRS1 inhibition [181, 200, 216, 253] in 3xTg-AD 
mice [141]. Hence, we hypothesized that INI administration, by favoring the 
IR-mediated activation of BVR-A, would prevent the alterations of the 
insulin signalling in the brain. Indeed, despite the reported beneficial effects 
of INI administration in humans [256-260], the molecular mechanisms that 
underlie the effects of insulin are still poor understood. In particular, it is not 
clear whether or not intranasal insulin overcomes insulin resistance by 
promoting the activation of the insulin signalling cascade [158, 261].  
Here, we provided some answers to this point by demonstrating that 
INI treatment promoted the activation of the IR and its downstream targets in 
the brain of both adult and aged 3×Tg-AD mice. Remarkably, improvement 
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of insulin signalling activation occurs along with an improvement of BVR-A 
activation both in the hippocampus.  
In agreement with our hypothesis, INI administration prevented the 
early impairment of BVR-A activation in 3×Tg-AD mice (Fig. 19). Indeed, 
an improved BVR-A activation seems to be useful to dampen IRS-1 hyper-
activation (as indexed by decreased Ser636 phosphorylation) (Fig. 20D), and 
it is also associated with an improvement of Akt phosphorylation (Fig. 20F) 
[198], which also prevents the failure of mTOR activation (Fig. 20G), in the 
hippocampus of 3×Tg-AD mice at 6 months of age. 
As previously reported, other than the brain insulin resistance 
phenomenon, also this non-physiological hyper-activation phase could 
produce deleterious effects in terms of learning and memory functions [262-
266]. Interestingly, by preventing the early alterations of the insulin 
signalling cascade in the 6-month-old 3×Tg-AD mice, INI also significantly 
ameliorated the short-term spatial learning in MWM, as well as the short-
term working memory in the NOR task (Fig. 17). Differently, the long-term 
memory (spatial and working) was not significantly affected by INI 
treatment, although we observed a trend toward an improvement of cognitive 
dysfunctions compared to vehicle-treated 3×Tg-AD mice. Other authors 
found that INI treatment was able to positively affect the long-term memory 
in C57BL/6 mice [267]. The discrepancy may be attributed to the differences 
in the experimental contexts and animals (transgenic versus non-transgenic 
mice, adult/aged versus very young), and mostly due to the use of different 
dosage of insulin and scheme of treatment (80 µg/every other day for 2 
months versus 900µg/day for 7 days), which may have affected the 
assessment of the cognitive phenotype in our experiments versus those 
reported by other authors.  
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Also of interest, to our knowledge this is the first study showing that 
INI treatment ameliorates depressive-like behaviour in the 6-month-old 
3×Tg-AD mice performing two different tests (Fig. 17). It is prudent, in fact, 
to test parallel depressive paradigms to strongly confirm phenotype. We 
therefore decided to perform two subsequent tests that are indicators of 
depressive behavior: forced swimming and tail suspension. We previously 
demonstrated that 3×Tg-AD mice show a depressive-like phenotype [165, 
166] that is completely reversed by INI treatment. 
Collectively, these observations agree with the well-known role of 
insulin in modulating synaptic plasticity [that is, LTP and long-term 
depression (LTD)] via Akt [200, 221]. Furthermore, insulin has a crucial role 
in the development and maintenance of excitatory synapses [200, 222] and 
has been shown to promote dendritic spine formation and excitatory synapse 
development through activation of the Akt/mTOR axis [200, 223].  In this 
picture, our results showing that silencing of BVR-A is sufficient to promote 
a dysfunction of LTP in rat brain slices (Fig. 18) represent an intriguing 
novelty, that, together with the observed impairment of the insulin signalling, 
further supports a role for BVR-A in the molecular mechanisms regulating 
cognitive functions (Fig. 17).   
The effectiveness of INI administration is evident also in aged (12 
months of age) 3×Tg-AD mice used to test the hypothesis that INI, by 
rescuing BVR-A impairment, prevents the onset of brain insulin resistance.  
Indeed, at 12 months of age these mice show a reduction of BVR-A 
activation along with clearly signs of insulin resistance including: (i) reduced 
IR levels and activation (Fig. 22B); (ii) increased IRS1 Ser636 
phosphorylation (Fig. 24C); (iii) uncoupling of Akt/mTOR signalling 
(Figures 22E&F). Interestingly, we found that INI treatment was able to 
recover the activation of BVR-A (Fig. 21) and to prevent the increased IRS1 
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inhibition (Fig. 22C), which results in a downstream improvement of both 
Akt (Fig. 22E) and ERK1/2 activation (Fig. 22D) finally leading to a 
significant recovery in terms of cognitive functions (Fig. 22F) [196, 200, 224, 
268]. In fact, at the behavioural level, 12-month-old 3×Tg-AD mice confirm 
the phenotype of younger 3×Tg-AD mice. In particular, INI treatment 
significantly enhances short-term spatial and working memory, as well as 
evokes depressive-like behavior in 3×Tg-AD mice (Fig. 17). As far as the 
long-term memory, INI treatment significantly decreases (-58%) the latency 
to cross platform location in the MWM and, although not significant, also 
ameliorates other behavioral endpoints of spatial and working memory in the 
3×Tg-AD mice compared to age-matched, vehicle-treated 3×Tg-AD mice. 
Surprisingly, we did not see a decrease of mTOR activation – which 
is among the kinases whose aberrant activity is known to mediate IRS1 
inhibition [197, 269] also in AD [179, 182, 270-273]  – in aged 3×Tg-AD 
mice following insulin treatment. However, we believe that the improvement 
of Akt activation together with the observed decrease of IRS1 
phosphorylation on a site known to be target of mTOR kinase activity 
[Ser636 [197], are indicative of an improved regulation of the Akt/mTOR 
axis.  
All these lines of evidence suggest that changes of BVR-A are 
strongly associated with alterations of the insulin signalling cascade in the 
brain. However, whether BVR-A is directly involved in the beneficial effects 
of INI both in adult and aged mice remained to be investigated. For that 
reason, we performed several in vitro experiments by using cells in which 
BVR-A was silenced to clarify the role of BVR-A in the mechanisms 
associated with insulin resistance (Figures 24&25). First, our results 
demonstrated that cells lacking BVR-A and treated with insulin develop 
insulin resistance rather than a physiological activation of the insulin 
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signalling (Fig.23 and Fig. 24). Indeed, an increase of IRS1 Ser636 
phosphorylation (Fig. 24D, column 5), a decrease of Akt activation (Fig. 24F, 
column 5) along with a persistent activation of mTOR (Fig. 24G, column 5) 
was observed.  Interestingly, these results agree with the molecular changes 
observed in 3×Tg-AD mice at 12 months of age (Fig. 22). At that age, we 
showed that BVR-A is required to recover cells from insulin resistance (Fig. 
24), since the above-cited alterations were retrieved only in control cells but 
not in cells lacking BVR-A, following the exposure to high dose insulin (500 
nM) (Fig. 24). These data, therefore, strongly support the mechanism 
hypothesized for INI-treated mice. The essential role for BVR-A is 
strengthened by the results collected in cells lacking BVR-A and treated with 
a BVR-A-mimetic peptide (Fig. 25).  As mentioned before, several sequence 
motifs within BVR-A structure were identified as possible protein–protein 
interaction sites [175]. Among these peptides, 290KYCCSRK was found to 
stimulate IR-mediated phosphorylation/activation of BVR-A finally leading 
to an increase glucose up-take in HEK cells [174, 205]. However, these 
observations were limited to the evaluation of basal glucose up-take.  Thus, 
we tested whether the 290KYCCSRK peptide could rescue cells from insulin 
resistance, and we demonstrated that in cells lacking BVR-A insulin 
promotes the activation of the insulin signalling cascade, and thus recoveries 
cells from insulin resistance, only if administered together with the peptide 
(Fig. 25). Indeed, decreased IRS1 inhibition, increased ERK1/2 and Akt 
activation, and decreased mTOR hyper-activity were observed (Fig. 25). 
The recovery of insulin signalling physiological activation in 3×Tg-
AD mice had beneficial effects also on Aβ and Tau pathology and is able to 
reduce the accumulation of oxidative damage both in adult and aged 3×Tg-
AD mice (Fig. 26). Accordingly, previous data demonstrated that insulin 
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deficiency leads to increased Tau phosphorylation, which was reversed by 
insulin administration directly in the brain [274-277], and that higher brain 
insulin concentrations may reduce amyloid oligomerization and toxicity 
[214], increase synaptogenesis [278], or modulate long-term potentiation and 
depression in the hippocampus, thus improving  learning and memory [279].  
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8. CONCLUSIONS  
 
Brain insulin resistance (BIR) could be a pivotal responsible for the 
progression of AD. Mechanistically, this condition is defined as an alteration 
on insulin response that could be caused by a reduction of brain insulin 
receptor sensitivity. Interesting, insulin signaling is impaired in post mortem 
brain tissue from AD patients [144], and as long as the role of insulin in cells 
growth and survival [99] is known, improving insulin action in neurons has 
emerged as an intriguing strategy to improve cognitive functions. Therefore, 
restoring insulin signalling activation in the brain by insulin treatment may 
provide therapeutic benefits in AD subjects. 
Among the regulatory points of this signaling, BVR-A was found to 
be impaired quite early during the progression of AD as demonstrated by 
several data collected by our group including this thesis work. Indeed, results 
showed here provide additional observations strengthen the hypothesis that 
the impairment of BVR-A is an early event in the progression of AD 
pathology and that it occurs before insulin signalling impairment and Aβ 
deposition. Interestingly, we demonstrate that recovering BVR-A activity 
allows to rescue early alterations of the insulin signalling cascade and to 
prevent the onset of brain insulin resistance. These changes are associated 
with a reduction of nitrosative stress, Tau phosphorylation and Aβ oligomers 
in brain, along with improved cognitive functions.  
In addition, we show for the first time that BVR-A impairment might 
favor an increased Aβ production in the brain through the regulation of 
BACE1 recycling, thus representing a possible molecular link between BIR 
and AD pathology. In this contest, BVR-A represents a molecular target to be 
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further investigated in AD.  Indeed, the modulation of BVR-A activity could 
delay the onset of brain insulin resistance along with an improved regulation 
of the APP cleavage, which would result in reduced Aβ levels in the brain.  
Strikingly, our results represent a step forward for the comprehension 
of the very early mechanisms responsible for the alteration of the insulin 
signalling cascade, finally resulting in brain insulin resistance, along the 
progression of AD neuropathology. The comprehension of the initiating 
molecular events is fundamental to develop new prevention strategies and to 
improve therapeutic strategies for the treatment of this disease.  
 
Within this scenario our data suggest the key role of BVR-A in the 
progression of AD neuropathology supporting the importance of this protein 
as a potential therapeutic target to prevent brain insulin resistance in AD and 
to stop or delay the neurodegenerative process. 
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